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Abstract 
Malignant melanoma is an aggressive type of skin cancer which urgently requires new and 
efficient treatment strategies. A novel targeted agent for advanced melanoma, vemurafenib, 
has shown high response rates among patients with BRAF mutation. However, relapses 
occur in almost all cases after a short period of progression-free survival. This project 
focused on the nature of vemurafenib resistance, specifically the role of the interaction 
between the cancer and the stromal cells. Here we used an extended melanoma cell panel 
to show that the stromal fibroblasts elicit strong protection of the melanoma cells against 
vemurafenib and do so via activation of mTORC1. We demonstrate that the fibroblast-
mediated protection relies on direct cell-cell proximity and/or contacts. However, we could 
not find evidence of gap-junction involvement. We found that fibroblasts alter gene 
expression in the melanoma cells, inducing an invasive dedifferentiated molecular 
phenotype associated with resistance to vemurafenib. Melanoma cells which have been in 
contact with the fibroblasts also had altered expression of the energy metabolism regulators 
which suggested a decrease in the mitochondrial function. We further show that the altered 
cancer metabolism can serve as a target for therapeutic intervention since the melanoma 
cells in co-cultures were more vulnerable to the treatment with the mitochondrial stimulant, 
dicholoacetate, than in mono-cultures. Finally, we explored the changes in the energy 
metabolism of the melanoma cells induced by vemurafenib and the mTORC1 inhibitor, 
everolimus. We found a decrease in the mitochondrial activity triggered by both agents and 
a reduction of lactate production after the treatment with vemurafenib.          
Our findings suggest lung fibroblasts as important regulators of melanoma response to 
vemurafenib. The results provide hints about potential targets for therapeutic intervention 
in order to overcome stroma-mediated protection.  
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Introduction 
Cancer and metastasis 
Cancers are a group of diseases characterized by abnormal cell proliferation, multiple 
genetic and genomic alterations and tumor formation. Cancers are distinct from benign 
tumors in their ability to metastasize – migrate to and invade distant tissues and organs. 
Metastatic disease poses the biggest threat to a patient often resisting available therapies 
and spreading to the locations where it cannot be treated surgically, and may eventually 
lead to death. The biology of metastasis, therefore, is one of the most important as well as 
the most clinically significant areas of cancer biomedicine.  
Metastasis during the late stages of cancer development occurs when a malignant cell leaves 
the primary tumor via blood or lymphatic vessels, travels to the other location in the body, 
docks to and establishes connections with the local microenvironment and begins to 
proliferate. The sheer complexity of this process means it has a very low success rate with 
only a few cancer cells being able to produce metastases. It is still debated whether this 
ability can be attributed to particular cells with certain characteristics or if it is an inherent 
property of all cancer cells, some of which encounter permissive conditions by chance [1]. It 
is clear, however, that the local non-malignant cells contribute greatly to metastasis 
development.  
Metastatic niche  
As the cancer progresses and spreads, it develops into a complicated structure where 
stromal cells are intertwined with the tumor, and, although not malignant themselves, 
engage in a complex molecular exchange with the cancer. The importance of stroma in 
cancer development and progression is difficult to overestimate with some studies 
suggesting that low cancer to stroma ratio in a tumor strongly correlates with the poor 
prognosis [2]. The composition of the tumor stroma depends on the anatomic location, but 
typically includes the extracellular matrix, fibroblasts, endothelial cells, cells of immune 
system and other locally present cells such as astrocytes in the brain (figure 1.1). Stromal 
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cells and the extracellular matrix at these sites respond to the presence of the cancer cells 
and create what is often referred to as the metastatic niche.  
Numerous mechanisms involved in the metastatic niche formation have been described 
(reviewed in [3]). It may come as no surprise that many types of cancer favour metastatic 
locations resembling stem cell niches, such as the bone marrow, and/or settle near the 
blood capillaries which supply the growing tumor with nutrients and oxygen. A metastatic 
niche would support the state of cellular dedifferentiation and provide soluble chemical 
signals, stimulating proliferation and survival of the cancer cells [4-6]. In addition, cell-cell 
contacts and adhesion have been shown to play an important role [7]. 
There are also reports suggesting that formation of the pre-metastatic niche is initiated 
before the cancer cells even arrive to the location. The pre-metastatic niche is “primed” by 
secreted factors and vesicles produced by the primary tumor, which leads to recruitment of 
stromal cells [8]. Together they create a permissive environment able to receive the 
metastatic cells and allow them to survive and proliferate.  
 
Figure 1.1 Formation of the metastatic niche in cancer. A niche is formed by the cells and the extracellular 
matrix of the local microenvironment. Tumor microenvironment stimulates cancer cell proliferation and 
evolves itself, leading to formation of reactive stroma, including cancer-associated fibroblasts (CAFs), which 
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promote conditions favouring malignancy and mutagenesis. Exosomes and bone-marrow derived cells released 
by a growing tumor initiate pre-metastatic niche formation at other secondary locations and prepare them to 
harbor circulating metastatic cancer cells. IMC - immature myeloid cells. Figure from Barcellos-Hoff MH. et.al 
[9]. 
Drug resistance in cancer and the role of stroma 
In oncology, surgical intervention has the strongest potential for complete cure. Other 
treatments like chemotherapy, immuno-therapy and targeted therapy alone or in 
combination often shrink the tumors and prolong survival, but are mostly unable to fully 
eradicate cancer. This is often due to drug resistance which develops in the tumors or 
circulating cancer cells that have not been removed.  
Drug resistance may be explained by a variety of mechanisms. These include existence of 
slowly dividing cancer cells (sometimes defined as cancer stem cells), which are not sensitive 
to anti-proliferation drugs (chemotherapy), increased drug metabolism and efflux, additional 
mutations and amplification of the mutated proteins, activation of the signaling pathways, 
which stimulate cell growth and survival, and other (reviewed in [10]).  
Latest findings have implicated stroma in the drug resistance, showing that it helps create 
conditions, not only favourable of metastasis development, but also enabling cancer cells to 
avoid therapy. The mechanism of the stroma-mediated drug resistance (SMDR) is dual as it 
relies on both secretion of multiple soluble factors [11, 12] and direct intercellular 
connections [13, 14].  
Soluble factors produced by the stroma cells include fibroblast-, hepatocyte-, insulin-like- 
and epidermal growth factors (FGF, HGF, IGF and EGF respecitvely), cytokines, transforming 
growth factor beta (TGF-β), stromal cell-derived factor 1α (CXCL12) and several others [15]. 
On the other side of the scale is SMDR mediated by intercellular adhesions, likely acting in 
concert with the soluble factor exchange. 
Contact-dependent SMDR: gap junctions 
In normal tissues, adhesion is crucial for cell survival as disruption of attachment to other 
cells and the extracellular matrix will lead to cell death by anoikis [16]. In cancer, docking to 
the local tissues enables metastasis and allows exchange of molecules and stimulation of 
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signaling in both the cancer cells and the stromal cells. There are several types of 
intercellular connections; however, in this project we focused our attention on the gap-
junctions.  
Gap junctions are composed of 6 connexin molecules arranged in a trasmembrane pore 
complex – connexon. Two connexons on the membranes of the two opposing cells bind to 
form a junction which allows transport of small molecules including ions, nucleic and amino 
acids and other, through a pore ranging from 11Å to 24Å in diameter (figure 1.2).  
 
Figure 1.2 Gap junctions scheme. Picture from https://thesalience.wordpress.com/neuroscience/the-chemical-
synapse/electrical-synapse/ 
In the nervous system connexons form electric synapses, which pass ions from neuron to 
neuron. In other tissues gap junctions directly transfer a wide variety of substances between 
the cells and have been shown to play a role in cellular proliferation and survival [17]. In 
cancer, gap junctions play a dual role either promoting or inhibiting tumor progression 
depending on the immediate circumstances. Connexon expression is often down-regulated 
in invasive malignancies suggesting that detachment from neighbouring cells is a 
requirement for metastasis [18]. At the same time, the cancer cells need to establish 
connections to the microenvironment of the metastatic niche which often involves 
formation of gap junctions [19]. Furthermore, it appears that gap junctions are also involved 
in SMDR. For instance, it was shown that gap-junctions between the astro-glial and the 
melanoma cells protect melanoma from chemotherapy by sequestering cytotoxic calcium 
ions out of the cancer cells [20, 21].  
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Other intercellular contacts are mediated via integrin and cadherin molecules, both of which 
can activate diverse signaling cascades in the participating cells [22, 23]. They may therefore 
be important for SMDR as well; however, we have not investigated this hypothesis further in 
the current project. 
Malignant melanoma  
Malignant melanoma is an aggressive cancer type which often spawns metastases, more 
rapidly than most of the other cancers. Malignant melanoma of the skin originates from the 
pigment producing cells called melanocytes, found in the basal skin layer. Melanocytes 
develop in the neuronal crest and migrate to the skin and hair follicles during embryogenesis 
[24]. After migrating to their final location, melanocytes differentiate into brunching cells 
with multiple protrusions. In the skin they make connections with up to 40 neighbouring 
keratinocytes to which they deliver a pigment called melanin [25]. Dark, non-transparent 
melanin, produced and transported in special organelles, melanosomes, surrounds the 
nuclei of keratinocytes, protecting them from the damaging ultra-violet radiation of the sun. 
Melanocytes are terminally differentiated, but occasionally begin to proliferate locally 
forming dark nevi on the skin. Most often, proliferation in the nevi is halted and they remain 
benign for the rest of the life. In rare cases, however, melanocytes undergo transformation 
and become malignant. 
Melanomas are relatively uncommon, but their incidence is on the rise. In Norway, it has 
increased eight-fold over the last 60 years with approximately 1500 new cases registered 
every year [26]. The most afflicted population is the fair-skinned individuals with high sun 
light exposure, suggesting an important role of the ultra-violet radiation in melanoma 
development [27].  
Melanomas may arise from an existing mole or appear de novo. They occur at different 
locations and affect people of all ages. Primary melanomas are often discovered on early 
stages as irregular-looking moles which can be completely removed with surgery. 
Melanomas are highly invasive, however, so it is extremely important that the primary 
tumor is removed entirely and on time. 
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Stages of melanoma progression 
Melanoma development in can generally be divided into four stages (figure 1.3). It starts 
with formation of a dysplastic nevus on the skin which expands horizontally while still within 
the limits of the basal membrane. This early stage of radial growth is followed by vertical 
growth during which the basal membrane becomes impaired and the malignant cells expand 
into the derma. The thickness of a malignant nevus has a strong correlation with patient 
prognosis [28], however, at this point a melanoma may still be removed. If left untreated, 
the melanoma cells would migrate to the distant locations of the body via blood or 
lymphatic vessels, and establish secondary tumors. Most common sites of melanoma 
metastasis include the brain, the lymph nodes, liver, lung and distant locations on the skin. 
At the last stage of its development, melanoma is practically impossible to eradicate. 5-year 
survival rate of stage IV melanoma patients is approximately 6 percent with median survival 
period of only 7.5 months [29]. 
 
Figure 1.3 Stages of melanoma progression. Dysplastic nevus is characterized by abnormal shape, uneven 
colouring, blurred borders and diameter of >6mm. Melanocytes undergo malignant transformation at this 
stage, characterized by inhibition of tumor suppressors which leads to proliferation radial-growth. Progression 
to vertical-growth phase is defined by increased expression of invasion-associated molecules such as N-
cadherin, matrix metalloproteinase-2 (MMP-2) and Vβ3 integrins. Thickness and ulceration of the melanoma 
during the vertical growth phase strongly correspond with the likelihood of metastasis. Finally, advanced 
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melanomas produce secondary tumors in the distant organs, most commonly lymph nodes, brain, lung and 
liver. Figure from Miller and Mihm; 2006 [30].  
 
BRAF mutation 
Melanoma cells carry a multitude of oncogenic mutations, the majority of which affect 
genes, encoding proteins of the proliferation supporting signaling, in particular, the mitogen-
activated protein kinase (MAPK) pathway. The MAPK pathway normally regulates gene 
expression by conveying signals from the cell surface to the transcription factors through a 
chain of phosphorylation events performed by the MAPK kinases – RAF, MEK and ERK (figure 
1.4). Each of the members of the MAPK pathway has several isoforms, some of which are 
frequently mutated in melanoma. These include NRAS [31] (HRAS and KRAS are mutated less 
often [32]), and BRAF [33] (oncogenic mutations in ARAF and CRAF have not been detected 
[34]). NRAS was shown to be mutated in approximately 15 percent of melanomas, while 
BRAF mutation is the most frequent, occurring in 60 percent of the patients [33].  
Mutations in BRAF (rapidly accelerated fibrosarcoma protein kinase B) gene usually involve a 
single amino acid substitution at the residue 600 from valine to glutamic acid (denoted 
BRAFV600E) which dramatically up-regulates BRAF activity. This mutation renders BRAF 
constitutively active which leads to signal propagation in absence of extracellular 
stimulation.  
Of note, BRAFV600E mutation in itself is not sufficient to induce melanocyte transformation 
and is often found in benign nevi [35]. In fact, constitutive activation of BRAF drives the cells 
to senescence, halting proliferation. However, additional mutations and activation of 
proliferation-related pathways can overcome the BRAFV600E-induced senescence and allow 
progression into a melanoma. One of the signaling events, implicated in this phenomenon is 
activation of mammalian target of rapamycin complex 1 (mTORC1). In the growth arrested 
melanocytes, its activity is normally suppressed [36]. In their recent publication, William 
Damsky et. al. have shown that reactivation of mTORC1 is necessary for BRAFV600E 
melanocytes’ progression to melanoma [36]. 
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Figure 1.4 MAPK pathway. MAPK pathway is initiated by the activation of receptor tyrosine kinases (RTK). RTK 
ligands include growth factors, such as HGF, EGF and FGF. Ligand binding leads to phosphorylation of the RTK 
by its own kinase domain, which triggers GTP-binding and activation of a small GTPase – RAS. Activated RAS 
then binds to the RAF kinase, such as BRAF, inducing a conformational change which results in BRAF activation 
and dimerization. Activated BRAF phosphorylates the next kinase of the MAPK cascade - MEK, which then 
phosphorylates the extracellular signal-regulated kinase (ERK). Activated ERK translocates into the nucleus 
where it interacts with the transcription factors stimulating expression of genes involved in cellular 
proliferation and survival. Mutations in BRAF make it unable to adopt the inactive conformation rendering the 
MAPK pathway constitutively active even in absence of the upstream signals. A BRAF inhibitor vemurafenib 
inhibits BRAF activation by blocking its active site. 
Vemurafenib and vemurafenib resistance 
BRAFV600E can be selectively inhibited by novel targeted therapeutic agents, such as 
vemurafenib (figure 1.4). Introduced into the clinic in 2012, vemurafenib is one of the most 
efficient drugs available for the melanoma patients who carry a BRAF mutation, and has a 
response rate of around 60 percent leading to 5.3 months of progression-free survival [37]. 
This is a considerable improvement for the patients whose median survival prior to the 
vemurafenib discovery was only 7.5 months. Unfortunately, despite the strong initial 
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response, melanoma develops resistance to vemurafenib in almost all cases, leading to 
relapse within one year of treatment.  
Mechanisms underlying vemurafenib resistance have been intensely investigated. It has 
been suggested that initial insensitivity to BRAF inhibition in melanoma, similarly to the 
absence of response in other cancer types with BRAF mutation, such as colorectal and 
thyroid cancer, may be explained by the loss of feedback inhibition of the RTK-mediated 
signaling by ERK [38-40]. This leads to increased activation of alternative signaling routes, 
such as the PI3K pathway, and sustained proliferation.  
Resistance has also been attributed to mutational activation of NRAS [41], increased 
production of mutant BRAF after the end of the treatment period, activation of MEK via 
elevated levels of MAP kinase kinase kinase COT and activation of alternative signaling 
pathways through RTK, where stroma-produced chemical factors may play a role (reviewed 
in [42]) (figure 1.5). 
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Figure 1.5 Vemurafenib resistance mechanisms. Resistance occurs when deactivation of the MAPK pathway 
(shown in blue) by vemurafenib abolishes the feedback inhibition of the RTK signaling. Other RTK-dependent 
cascades, such as the phospho-inositide-3-kinase (PIK3) – mTORC1 pathway then get activated and lead to 
continued proliferation (shown in red). Resistance depends on several mechanisms, including activation of the 
RTK by the stroma-produced growth factors (such as HGF), mutational activation of NRAS and MEK alongside 
up-regulation of COT all of which lead to reactivation of the MAPK activity. Modified from Holderfield M., et al, 
[42].  
 
Vemurafenib resistance is often classified as either innate or acquired. Clinically, these are 
two distinct conditions depending on the disease progression state. Initial lack of response 
defines innate resistance, while patients who go through a period of disease regression and 
then relapse after several months appear to have acquired resistance during treatment. 
However, the cells that do not respond to vemurafenib, be it initially, or after prolonged 
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treatment with the drug, are very similar on the molecular level. As summarized in table 1.1, 
such cells can be characterized by several distinctive features.  
 
Resistant phenotype feature Source 
Loss of feedback inhibition of RTK => activation of alternative signaling [38, 41] 
Overexpression of BRAFV600E [43] 
Up-regulation of COT [44] 
Stroma secreted factors stimulate proliferation-driving signaling [45] 
Low levels of the microphthalmia-associated transcription factor (MITF) 
expression 
[46] 
High expression of invasion-associated proteins [46] 
Table 1.1 Molecular alterations in the vemurafenib-resistant cells. 
 
Resistance-associated properties may occur at any stage of the cancer progression, prior to 
the treatment, or after, in those cells where the MAPK inhibitors failed to induce cell death. 
It has been shown that in the sensitive cells, vemurafenib may either trigger apoptosis [47-
49] or inhibit proliferation, driving the cells into a senescent state in which they do not divide 
[50-52]. This depends on the concentration of the drug that the cells are exposed to and in 
vivo may rely on vascularization of the tumor, among other factors. Those cells that halt 
proliferation, but do not undergo cell death, can be considered sensitive, but pose a hidden 
danger as the senescent state may be overcome. Over time mutations and phenotypic 
changes may accumulate and re-activate the proliferation-related signaling eventually 
resulting in development of the resistant phenotype (figure 1.6). 
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Figure 1.6 Potential scenarios underlying innate and acquired resistance to vemurafenib in melanoma. 
To summarize, resistance relies on genetic instability and activation of oncogenic signaling. 
Stromal cells can contribute to both by creating aggressive pro-mutagenic environment 
within a tumor and by supplying proliferative signals which drive cancer growth. The extent 
to which the cancer cells interact with the stroma may define their sensitivity to therapy 
both before the drug is administered and afterwards during relapse of the disease. From this 
perspective, a better understanding of the tumor-stroma interactions may open 
opportunities for therapeutic interventions that could not only target rapidly proliferating 
cells, but prevent the SMDR. 
 
 
The role of mTORC1 in SMDR against vemurafenib  
One of the insights into stroma – mediated vemurafenib resistance in melanoma came from 
a comprehensive screening of multiple tumor and stroma cell lines cultured together and 
subjected to various therapeutic agents [45]. It was shown that the presence of stroma 
weakens drug response in cancer cells which was most apparent in the melanoma-fibroblast 
pairing treated with vemurafenib. In line with these observations, members of our group 
have shown higher viability of the melanoma cells in co-culture with the fibroblasts rather 
than alone after treatment with vemurafenib (figure 1.7). 
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Figure 1.7 Improved relative viability of the melanoma Melmet 5 cells in co-culture with fibroblasts after 72h 
treatment with vemurafenib, measured by bioluminescence. Statistical significance. Data indicates average ± 
SEM (n ≥ 3); *, p ≤ 0.05. Vasiliauskaite K. et al., unpublished.  
 
Ravid Straussman et al. have identified that fibroblast-induced protection occurs due to the 
HGF secreted by the fibroblasts [45]. HGF is a ligand of a RTK c-Met, located on the 
melanoma cellular surface, which is phosphorylated upon HGF binding.  
c-Met phosphorylation leads to the activation of downstream cascades including MAPK 
pathway and PI3K (figure 1.5). One of the most prominent PI3K downstream targets is 
mTORC1 (figure 1.5). In cancer PI3K – mTORC1 signaling cascade is one of the frequently up-
regulated pathways [53], whose activation helps the cancer cells bypass MAPK inhibition, i.e. 
by vemurafenib. Activation of mTORC1 signaling is associated with increased protein 
production and cell proliferation, among other effects [54].  
mTORC1 activates S6 kinase (S6K), which phosphorylates the ribosomal protein S6 (figure 
1.5). S6 is a component of the ribosomal 70S subunit and regulates protein translation. 
Dephosphorylation of S6 after vemurafenib treatment predicts strong response in vitro and 
in vivo [55]. Conversely, if S6 stays phosphorylated despite vemurafenib, it is likely that such 
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cells would not be affected by the treatment [55]. Members of our research group have 
previously shown that vemurafenib treatment results in reduced level of pS6 in BRAFV600E 
melanoma cells when they were cultured alone, indicating suppression of the mTORC1 
activity. However, in the presence of fibroblasts, this suppression effect of vemurafenib on 
pS6/mTORC1 was abolished resulting in significantly higher levels of pS6 (figure 1.8). This 
implicates mTORC1 in the stroma-mediated resistance in melanoma (figure 1.8).  
 
 
Figure 1.8 Phospho-S6 levels in Melmet5 melanoma cells either in mono-culture or in co-culture with stromal 
fibroblasts treated with vemurafenib, relative to untreated control. pS6 levels were strongly decreased in 
mono-culture samples, while co-culture with fibroblasts retained S6 phosphorylation. Data indicates average ± 
SEM (n=3); *, p < 0.05. Vasiliauskaite K. et al., unpublished. 
 
Transcriptional state and sensitivity to vemurafenib 
A growing tumor harbours increasingly diverse microenvironments with the centre of a 
tumor being entirely different from the periphery. Such difference in conditions coupled 
with genetic heterogeneity makes tumor architecture complex and uneven. Thus malignant 
cells in the same patient derived from different locations in the tumor may carry drastically 
different phenotypes. In 2008, Keith S. Hoek and colleagues suggested classification of the 
metastatic melanoma cells into proliferative and invasive phenotypes characterized by 
differential gene expression and distinct ability to migrate [56]. They proposed that 
melanoma cells are able to switch between the two phenotypes depending on the 
Melmet5 
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surrounding microenvironment. Such plasticity allows cells to survive harsh conditions and 
travel to the secondary locations where they may switch their phenotype again. In their 
study, Hoek K. et. al [56] proposed a model for melanoma progression, according to which, 
the metastatic cells undergo several rounds of transition between the phenotypes so as to 
survive and proliferate in different contexts.  
Cells of “proliferative” phenotype carry a distinct pattern of gene expression with high levels 
of melanocyte lineage genes, such as the MITF and its target genes. By contrast, the 
“invasive” cells have low expression of MITF and its targets, but high expression of 
“mesenchymal” genes, e.g. those involved in Wnt, TGF-β and Axl signaling [46, 57]. 
Importantly, several recent studies found an association between the molecular phenotype 
and sensitivity to vemurafenib. It has been shown that cells of the proliferative phenotype 
are sensitive to MAPK inhibitors, while the invasive phenotype cells are more resistant [57, 
58]. The authors concluded that distinct molecular phenotype may be the cause of 
resistance to anti-MAPK therapy, and proposed MITF/AXL ratio as a “predictive indicator” of 
the treatment response [57, 58].  
 
The role of energy metabolism in cancer 
An aggressive resistant phenotype, also referred to as a state of de-differentiation, is 
associated with several functional changes. Among them, altered energy metabolism has 
been described as a distinct property of malignant cells and one of the hallmarks of cancer 
[59].  
There are two metabolic pathways involved in ATP production in the cells (figure 1.9). The 
first involves generation of the proton gradient in the mitochondria using several substrates, 
including glucose-derived pyruvate. The proton gradient allows phosphorylation of ADP into 
ATP. This pathway is termed oxidative phosphorylation (OxPhos) because it requires the 
presence of oxygen as an electron acceptor. OxPhos generates up to 36 molecules of ATP 
per one molecule of glucose and thus is the most efficient way to produce energy for the 
cell. Most cells utilize this pathway if enough oxygen is present, however, under certain 
conditions, the other mechanism may be used.  
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The second pathway can be defined as glucose fermentation in the cytoplasm and results in 
production of lactate and two molecules of ATP. This pathway consists of two parts – 
glycolysis which ends with production of 2 pyruvate molecules, and conversion of pyruvate 
into lactate. This pathway does not require oxygen and is therefore mostly used in hypoxic 
conditions. In some cases, cells may utilize this pathway in presence of oxygen – a 
phenomenon termed aerobic glycolysis.  
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Figure 1.9 Intracellular energy metabolism. Glucose is imported into the cell via glucose transporters where it 
undergoes glycolysis. Glycolysis consists of ten chemical reactions that result in production of 2 ATP and 2 
pyruvate molecules. Pyruvate can then either be converted into lactate by lactate dehydrogenase (LDH) and 
exported out of the cell, or uptaken by the mitochondria and converted into acetyl CoA. Other substrates, such 
as fatty acids can also be used to produce acetyl CoA which then enters the tricarboxylic acid (TCA) cycle. 
Consequent reactions of the TCA cycle result in reduction of 3NAD⁺ and FAD⁺ into NADH and FADH2. Together 
with NADH produced during glycolysis and conversion of pyruvate into acetyl CoA, NADH and FADH2 donate 
electrons to the complex I and complex II respectively. The electrons are then passed to complex III and to 
complex IV where they are accepted by oxygen with production of water. Complexes of the electron transport 
chain facilitate pumping of protons from the matrix of the mitochondrion into the intermembrane space. 
Abundance of protons between the mitochondrial membranes creates a gradient which allows protons to leave 
back into the matrix through the complex V (ATP-synthase). As the protons pass through it, the ATP-synthase 
phosphorylates ADP with production of up to 36 molecules of ATP per one molecule of glucose as an original 
substrate. Together all of the events in the mitochondria that result in production of ATP are termed oxidative 
phosphorylation (OxPhos). The output of OxPhos is adjusted to meet the current ATP demands of the cell. 
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Warburg effect  
One of the first researchers to connect altered glucose metabolism and cancer progression 
was Otto Warburg, who observed that the cancer cells tend to utilize aerobic glycolysis to 
produce energy rather than rely on OxPhos [60]. This tendency to use glucose fermentation 
by cancer cells, termed the Warburg effect, has been traditionally linked to the rapid 
proliferation of the cancer cells. Growth and division require building blocks, however, in the 
process of OxPhos, many of the organic molecules are being degraded. On the contrary, 
aerobic glycolysis does not require additional substrates and can be more convenient for the 
dividing cells to use in case there is sufficient amount of glucose [61].  
Most recently, it has been shown that the metabolic preference is dependent on a wide 
range of extra- and intracellular factors [62]. ATP production is acutely regulated by 
inhibition and activation of metabolic enzymes while long-term metabolic shifts occur 
through gene expression regulation. It has also been demonstrated that activation of 
proliferation-related signaling cascades in cancer cells can regulate energy metabolism [63]. 
Several studies have shown that up-regulated aerobic glycolysis is one of the manifestations 
of invasive phenotype in cancer [64-66]. Factors that contribute to such regulation have 
since been meticulously dissected. 
It has also been shown that the MAPK pathway activation decreases the number and activity 
of the mitochondria [67]. With reduced use of the OxPhos pathway, the cancer cells are 
driven to up-regulated aerobic glycolysis. This creates an acidic environment which further 
promotes dedifferentiation and resistant phenotype in the cancer cells [68]. Studies have 
shown that vemurafenib as well as MEK inhibitors alone or in combination reduce this effect 
and stimulate expression of the OxPhos regulating genes, such as peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PPARGC1A encoding PGC1-α) [67, 69, 70]. 
Three-day treatment with vemurafenib results in higher number and increased function of 
the mitochondria, which constitutes an evasion mechanism that allows cell survival in 
presence of MAPK inhibitors [67, 71]. Increase in OxPhos is accompanied by up-regulation in 
MITF expression, indicating that metabolic alterations are closely related to the phenotype 
shift. 
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Considering this connection between metabolism and malignant phenotype, using 
metabolism-regulating drugs in combination with MAPK inhibitors may improve response to 
therapy.  
 
Cancer metabolism as a target for therapy 
Recently, cellular metabolism has emerged as an attractive target for therapeutic 
intervention. Some studies suggest that inhibition of enzymes, such as poly (ADP ribose) 
polymerase-1 (PARP-1), involved in regulation of NAD-factor red-ox balance could be 
beneficial [72]. In addition, most cancers demonstrate increased capacity to sustain reactive 
oxygen species (ROS)-induced stress. This largely relies on antioxidant systems, which can 
also serve as targets to prevent increased cancer cell survival. This is particularly promising in 
melanoma, where the OxPhos pathway, and, as a consequence, the ROS production, are up-
regulated after vemurafenib treatment as one of the compensation mechanisms [73]. 
Finally, inihibition of the lactate exporters, MCT1 and MCT4 proteins, which transport lactate 
accumulated during aerobic glycolysis out of the cells, may prove useful as well [74, 75].  
A substantial body of research has described attempts to reverse the Warburg effect by 
blocking glycolysis [76, 77]. To that end, researchers used dichloroacetic acid (DCA), which 
blocks pyruvate dehydrogenase kinase (PDK). PDK inhibits pyruvate dehydrogenase (PDH), 
which mediates conversion of pyruvate into acetyl CoA. In other words, DCA stimulates 
OxPhos by inhibiting OxPhos inhibitor, PDK. DCA was shown to efficiently reduce cancer cell 
growth and invasion in vitro and in vivo, [78-80] and may therefore be considered for clinical 
use [81]. In the current project, we investigated whether DCA could be used to reverse 
stroma-mediated metabolic changes in the melanoma cells.  
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Aims of study 
Previous studies in our group have revealed that the stromal cells can protect Melmet5 
melanoma cells against targeted drug, vemurafenib, in vitro. The current project aimed to 
expand the melanoma cell line panel in order to verify this finding and investigate biological 
mechanisms involved at the molecular, signaling and metabolic levels.  
Within the limits of this master’s assignment, we defined the following sub-goals: 
1. Verify the fibroblast-induced protection against vemurafenib in four melanoma cell 
lines. 
2. Investigate whether the protection effect is mediated via stroma-secreted soluble 
factors or relies on the immediate cell-cell connections. 
3. Investigate potential biological mechanisms involved in the protection by studying 
changes in the gene expression and signaling in melanoma under the influence of 
fibroblasts. 
4. Study therapeutically induced alterations of the melanoma energy metabolism using 
novel technology provided by Seahorse Bioscience. 
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Materials and Methods 
Cell lines 
Four human malignant melanoma cell lines derived from distant metastases were used in 
this project: Melmet5, HM8, HM19 and Patient-3-pre. Human lung fibroblasts WI-38 were 
used as a stromal cell line. 
 
 Tissue of origin Received from 
Melmet 5 Lymph node metastasis 
Norway, 
Radiumhospitalet 
HM8 Brain metastasis 
Norway, 
Radiumhospitalet 
HM19 Brain metastasis 
Norway, 
Radiumhospitalet 
Patient-3 pre Lymph node metastasis 
University of Sydney, 
Sydney, Australia 
WI-38 Lungs 
ATCC. Product number 
CCL-75, Lot number: 
58483158 
 
 
Cell culturing 
All cancer cells were cultured as cell monolayer in tissue cultured flasks in RPMI medium 
supplemented with 10% FBS, 2mM Glutamax, and, in most cases, 1% Penicilin and 1% 
Streptavidin for protection against bacterial infections. The WI-38 fibroblasts were cultured 
in EMEM medium with the same supplements. All cells were kept at 37C° in an incubator 
with 5% atmospheric CO2 and were routinely tested for mycoplasma.  
Table 2.1: Cell line sources 
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 Subculturing 
All cell lines were regularly split once the cell confluence approached 90-95%. EDTA 
0.02% was used for detachment of all cancer cells, while WI-38 fibroblasts were 
detached with 0.05% Trypsin - EDTA solution. The cells were then collected, 
centrifuged and resuspended in fresh medium. 10µl of the cell suspension was 
stained with equal volume of trypan blue and used for counting. Automated cell 
counter countess™ was used to estimate the number of cells in suspension and their 
viability, based on the assumption that trypan blue only penetrates dead or dying 
cells with compromised membranes. 
 Freezing 
To prepare frozen cell stocks, cells were detached, collected and counted as 
described above. One million cells per tube in medium containing 10% DMSO were 
frozen in a -80C° freezer before being transferred to liquid nitrogen tanks for long 
term storage. 
 Thawing 
Frozen cells were rapidly thawed in a 37C° water bath and immediately transferred 
into tubes with pre-warmed medium. To remove remaining DMSO, the cell 
suspension was centrifuged and resuspended in fresh medium. The cells were then 
transferred to tissue culture flasks.  
Virus production and transduction of cancer cells 
For the majority of experiments, melanoma cell lines expressing green fluorescent protein 
and luciferase (GFP-luc) fusion protein have been used. Lenti-viral transduction was done to 
achieve stable expression. The virus was produced using 293HEK (human embryonic kidney) 
cells in several steps (figure 2.1).  
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Figure 2.1 Lentivirus production and cancer cell transduction in steps 
 
1. Three plasmids: pMD2.G encoding viral envelope proteins; psPAX.2 with packaging 
genes; and Luc-GFP #10-Neo plasmid carrying the genes of interest – luciferase and GFP 
under control of the ferritin promoter (a gift from prof. G Merlino [82]); were mixed using 
1,5µg, 3,75µg and 5µg respectively. Optimem 479µl was added to the plasmid mix and, 
separately, 450µl of Optimem was mixed with 50µl of Lipofectamine-2000.  
2. After 5min incubation at room temperature, the plasmid – Optimem mix and the 
lipofectamine-2000 in Optimem were combined and kept at room temperature for 20min. 
The resulting transfection solution was then applied to the semi-confluent HEK293 cells in a 
petri dish with 5ml of growth medium. 1.4mln 293HEK cells had been seeded out one day 
prior to transfection. 
3. The medium was replaced with fresh RPMI 1 day later and 2 days after that, the 
medium was collected and centrifuged in order to remove the cell debris. The supernatant 
containing virus was collected, filtered through 0.45µm low-protein binding filter, aliquoted 
and frozen at -20C°.  
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4. 50000 293HEK cells/well were plated into a 24-well plate in supplemented RPMI 
medium and cultured for two days. 100µl, 50µl and 10µl of the virus stock solution were 
added to RPMI to the total volume of 500µl in each well. In addition, half of the wells 
received 10µg/ml polybrene. 18h later, the medium was replaced with fresh virus-free RPMI. 
24h after that, successful transduction was verified using a fluorescent microscope. It was 
determined that the highest volume of the virus stock produced the strongest transduction 
efficacy. Polybrene did not influence the outcome of the test. 
5. For transduction of cancer cells, 300µl of virus stock was combined with 10µg/ml 
polybrene in 500µl of RPMI medium and applied to the cells cultured in a well of a 6-well 
plate.  
6. The medium was changed 1 day after transduction and a day after, the transduced 
cells were inspected for GFP with a fluorescent microscope.  
7. After 5 passages, the cells were sorted by flow-cytometry in the cell sorting core 
facility of the Radium Hospital in order to purify cells with high levels of GFP-luc expression.  
 
All of the steps involving virus production and transduction were performed at the specially 
designed biosafety level 2 laboratory which is used exclusively for this purpose and is 
equipped with neutralizing agents and protective clothing.  
 
In vitro cancer cell viability assays 
 
Testing drugs targeting oncogenic signaling pathways in cancer cell mono-
cultures 
To evaluate drug effects on cancer cell viability, cancer cells were plated in 100µl medium 
into 96-well plates, incubated overnight and treated with BRAFV600E inhibitor vemurafenib 
(stock solution 20mM in DMSO) dissolved in 100µl of fresh medium in concentrations of up 
to 10µM for 72 hours. The mTORC1 pathway inhibitor everolimus (stock solution 20µM in 
DMSO) was applied following the same protocol in concentrations from 5nM to 100nM. At 
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the end of the treatment, cell viability was measured using bioluminescence or MTS analyses 
described below. 
Testing dichloroacetic acid in mono- and co-cultures 
Dichloroacetic acid (DCA) was tested on melanoma cells in mono-culture and in co-culture 
with WI-38 fibroblasts in order to investigate tumor cells’ sensitivity to metabolic alterations. 
Cells were seeded out in 100µl medium (cell numbers specified in table 2.2) and incubated 
for 72 hours in order to induce stroma-mediated phenotypic changes in the cancer cells. 
Freshly prepared DCA (2M stock solution in PBS) was then applied in 10mM, 20mM and 
30mM concentrations, in 100µl of RPMI medium. The plates were incubated further for 48 
hours after which, the viability of the cancer cells was measured using the bioluminescence 
assay, described below.  
 
 Melmet 5 HM8 
Mono-
culture 
5500 4000 
Co-culture 1500 1000 
WI-38 in co-
culture 
4000 4000 
 
 
 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) 
MTS is a tetra-zolium dye which is converted into a coloured formazan product by 
intracellular reductases found in metabolically active viable cells. The quantity of the 
formazan product and, therefore, colour intensity, is directly proportionate to the number of 
living cells in culture. MTS was diluted with medium 1:5 and added to the cells for 
approximately 1-hour long incubation at 37C°. Absorbance at 490nm was then measured 
using a 1420 Multilabel Counter Wallac® plate reader.  
 
 
Table 2.2 Number of cells per well seeded for mono-culture and co-culture 
experiments on 96-well plates for testing DCA. 
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Cell viability measurement by bioluminescence analysis 
All cancer cells lines in the current project were genetically modified to stably express GFP-
Luciferase. Luciferase uses luciferin as a substrate in a reaction which results in light 
emission – bioluminescence. Reading the emission signal intensity allows tracking of the 
viable cancer cells and is proportional to their number. Luciferin (stock solution 20mg/ml) 
was mixed with medium at a ratio 1:200 and added to the cells for 10 minute incubation in 
the dark. The emitted bioluminescence was then measured by a 1420 Multilabel Counter 
Wallac® plate reader. Plates with opaque white walls specially designed for bioluminescence 
measurements were used in these experiments.  
Co-cultures of cancer cells with WI-38 fibroblasts  
Cell-cell contact-based cultures 
To explore whether stromal cells influence cancer cells, we made use of co-cultures 
consisting of cancer cells and lung fibroblasts WI-38. For these experiments, both cancer 
cells and the WI-38 fibroblasts were detached, collected and counted in the similar manner 
as during cell splitting described above, to achieve the desired numbers of cells per well 
(table 2.3). Appropriate volumes of cell suspensions were then mixed and plated in 96-well 
plates in 100µl of medium to allow direct contact formation. RPMI medium was used in such 
experiments, which fibroblasts tolerated well. Drugs were applied in the same manner as on 
mono-cultures and the treatment lasted for 72 hours. Viability of the cancer cells by the end 
of the experiment was determined by measuring bioluminescence. 
 Melmet 5 HM8 HM19 
Patient-3-
pre 
Mono-
culture 
2500 4000 4000 2500 
Co-culture 1250 2000 2000 1250 
WI-38 in co-
culture 
1250 2000 2000 1250 
 
 
Table 2.3 Number of cells per well seeded for mono-culture and co-culture 
experiments on 96-well plates. 
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Cultures on trans-well insert plates 
 
 
 
To explore whether stromal cells have an influence on cancer cells via soluble factors, we 
used trans-well plates with inserts allowing separation of the cancer cells from stroma cells 
while simultaneously keeping them in shared conditions. 0.4 µm pores of the insert 
membrane eliminate direct cell-cell contacts but the medium containing soluble factors is 
exchanged freely. 
 
 24-well plates for viability analysis 
8 000 melanoma cells were placed into the inserts, while the bottom wells had 15 000 
fibroblasts (or 24 000 melanoma cells for control). When seeding, 700µl of medium was used 
in the bottom wells, and 100µl was applied to the cells in the inserts. The cells were 
incubated overnight before vemurafenib was added in different doses. When adding the 
drug, the inserts were temporarily removed and kept in a separate clean dish, while the 
medium was being changed in the bottom wells. The medium from the inserts was then 
removed and they were returned to the original plate. Finally, fresh medium containing 
drugs was placed into the inserts. This technique made it possible to avoid drying of the 
cells. After 72 hours of incubation with vemurafenib, MTS assay was performed on the 
cancer cells in the inserts to determine their viability.  
 
Figure 2.2: Scheme of a trans-well with an insert 
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 6-well plates for molecular analyses 
6-well plates with inserts were used to prepare samples for western blotting, flow cytometry 
and PCR. In a similar manner as for the experiments on 24-well plates described above, 200 
000 melanoma cells were seeded in the inserts, while 250 000 fibroblasts (or 300 000 cancer 
cells for control) were placed in the bottom wells. 1 day after seeding, the medium was 
replaced with fresh RPMI with supplements containing 1µM Vemurafenib. After 24-hour 
incubation, cells in the inserts were thoroughly washed with PBS, detached with trypsin-
EDTA and collected for further analyses.  
 Melmet 5 HM8 WI-38 
Bottom well 24000 24000 15000 
Insert 8000 8000  -  
 
 
 Melmet 5 HM8 WI-38 
Bottom well 300 000 300 000 250 000 
Insert 200 000 200 000  -  
 
 
Adhesion assay 
To evaluate how well cancer cells attach to the stromal cells, adhesion assay was performed. 
15000 fibroblasts per well were seeded into a white-wall 96-well plate for bioluminescence 
measurement and incubated until full confluence. The wells were then washed with PBS to 
remove all serum. Melanoma cells, 25 000 per well, in 100µl serum-free medium were 
added to the fibroblasts and incubated for 1 hour. Half of the wells were then thoroughly 
washed with PBS to remove the non-attached cancer cells, while the other half was left for 
data normalization. Adhesion efficacy was evaluated by measuring bioluminescence 
produced by the adherent melanoma cells as compared to the signal from the wells which 
had not been washed and expressed in percent.  
Table 2.4: Number of cells per well seeded in 24-well plates with inserts. 
Table 2.5: Number of cells per well seeded in 6-well plates with inserts. 
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Western blotting 
Western blotting is a semi-quantative method for protein separation from cell- or tissue-
derived samples. It is used to determine if a certain protein is present, estimate its 
comparative amount in a sample and identify certain modifications such as phosphorylation. 
The results can be analyzed visually, however, it is also possible to quantify the intensity or 
the acquired signal with special software.  
Although there is room for variation in western blotting, in general, the procedure consists 
of eight steps (Figure 2. 3). 
 
 
 
 
Figure 2.3 Scheme of a western blotting experiment  
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In this study, samples for western blot analysis were prepared from collected cells which 
were washed with PBS in order to remove remaining FBS. The cell pellets were lysed by 
sonication while being in the lysis buffer (150mM NaCl, 50mM Tris pH 7.5, 0.1% Nonidet 
P40) in the presence of phosphotase and protease inhibitors. Protein concentration was 
estimated in each sample with the use of Pierce™ BCA protein assay kit according to the 
supplied protocol. Prior to loading, the samples were kept at 75C° for 5 minutes in solution 
with reducing agent SDS, and loading buffer.  
1. Samples, containing equal amounts or proteins, typically 20µg, were loaded into the 
gel pockets. Nu-PAGE 4-12% Bis-Tris 1.0mm x 12 well gels were used. In addition, at 
least two protein “ladders”- commercially available samples with coloured proteins 
of known sizes (See Blue®Plus 2 prestained standard, Invitrogen), were used in each 
western blotting experiment.  
2. Electric charge of 150V was applied to the gel, making the proteins, all negatively 
charged by the reducing agent SDS, move downwards to the positive pole. Bigger 
proteins move slower than smaller ones, resulting in size-based separation in the 
process of electrophoresis. Current project involved 1-2 hour long electrophoresis 
performed in MES buffered solution. 
3. The gel was pressed against the PVDF membrane and “sandwiched between” several 
layers of sponges and paper for semidry transfer. The “sandwich” was placed 
between two plates, which conduct electrical charge forcing the proteins out of the 
gel and onto the membrane. Transfer took 1 hour at 400mA.  
 
 
 
 
 
 
 
Figure 2.4 Membrane handling in western blotting. Step 1. The membrane strongly binds proteins from 
the gel. Step 2. Membrane blocking with dry milk or bovine serum albumin (BSA) to avoid unspecific 
binding of the Abs in the next steps. Step 3. Primary Abs are applied and bind very selectively to the 
protein of interest. Step 4. Secondary Abs conjugated with polyclonal horseradish peroxidase bind to the 
primary Abs.  
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4. Protein transfer onto the PVDF membrane was verified with Amido-Black staining, 
which unspecifically binds to the proteins. The membrane was then blocked with 
either 5% bovine serum albumin (BSA) or 5% dry milk in Tris-buffered saline Tween20 
(TBST) solution. Blocking solution corresponded to the solution for the primary Abs 
recommended by the Abs’ producer. Blocking was performed for 1 hour at room 
temperature (RT). 
5. Primary Abs in recommended dilutions were applied in either 5% BSA or 5% dry milk 
solutions onto the membranes overnight at 4C°. 
6. After being washed with TBST 3 times for 10 minutes, the membrane was incubated 
with appropriate secondary Abs in the same solution as the respective primary Abs 
for 1 hour at room temperature. Secondary Abs were diluted 1:3500 in either 5% BSA 
or 5% dry milk solution. 
7. Finally, the membrane was washed 3 times and covered with Super Signal® West 
Dura Extended duration substrate.  
8. The membrane was then immediately visualized in G:Box membrane visualization 
chamber at various exposures depending on protein signal intensity. 
 
 
 
 
Real time polymerase chain reaction (PCR) 
Real time PCR allows quantification of the gene expression levels in cells. mRNA is isolated 
from the cells and turned into cDNA by reverse-transcriptase. Using primers for genes of 
interest, a PCR reaction on the total cDNA is then initiated. Special probes, complementary 
to the sequences within the same genes are also added. They attach to the sequence and 
are then cleaved away by the moving DNA polymerase. Probes carry fluorescent tags which 
are inactive in the bound state, but turn fluorescent after being cleaved. As the PCR 
propagates, the fluorescent signal intensity grows exponentially. The number of the cycle 
during which the signal crosses the threshold is called the Ct value (figure 2.5). Ct value is 
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determined by how much of the target cDNA if any was present in the sample at the start of 
the PCR and is thus related to the expression levels of the corresponding gene.  
 
 
Figure 2.5 Illustration of a real time PCR experiment. The signal intensity crosses a threshold after several 
cycles. The number of the cycle reflects the amount of template DNA in the sample.  
RNA isolation and cDNA synthesis 
The cancer cells for the real time PCR were collected from the inserts of the 6-well trans-well 
plates. The inserts containing cancer cells were lifted and placed into a separate empty 6-
well plate where they were treated with trypsin-EDTA. The cells were collected, centrifuged, 
resuspended in 500µl TRIzol® reagent and stored at -80C°. After thawing, 100µl chloroform 
was added to each sample, which were then centrifuged at 12000xg for 15min at 4C°. The 
colourless RNA-containing phase without TRIzol was removed and placed into RNAse-free 
test-tubes where RNA was precipitated using 250µl of isopropyl alcohol per sample. 3µl of 
acrylamide was also added to the mixture to make it easier to locate the RNA pellet in the 
following steps. The samples were transferred into -20C° freezers for overnight incubation. 
The samples were then centrifuged at 12000xg for 40min at 4C°. The supernatant was 
carefully removed and the RNA pellet was resuspended in 500µl of 75% ethanol and 
centrifuged at 12000xg for 15min at 4C°. The supernatant was removed; the pellets were 
briefly air-dried to remove all ethanol and resuspended in 50µl of RNAse-free water. Finally, 
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the samples were incubated at 55C° for 5-10min and placed on ice while the RNA 
concentration was measured using Nano Drop.  
 
Biosciences qScript™ DNA synthesis kit was used to prepare 1000ng of cDNA according to 
the protocol supplied by the manufacturer. The following program was applied on the 
thermo-cycler GeneAmp® PCR system 9700: 
- 22C° – 5min 
- 42C° – 30min 
- 85C°– 5min 
- 6C° – ∞  
Final cDNA concentration was brought to 12,5ng/µl in all samples.  
 
Quantitative real-time PCR 
Forward and reverse primers were mixed with the corresponding fluorescent probes and 
SuperMix (Quanta Biosciences, PerfeCTa™) containing nucleotides, MgCl₂ and DNA 
polymerase. 1µg/µl of cDNA was then added to each sample (table 2.6). 
 
 x1 well x2 wells 
SuperMix 13.5 
Mix 49.7 
Primer forward 0.81 
Primer reverse 0.81 
Probe 0.54 
cDNA 2.16 4.32 
Water 9.18  
Total 27  54 
Table 2.6 Volumes of reagents used to prepare PCR samples  
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Every sample was divided into two wells using 25µl for each in a PCR plate to create two 
technical replicates. The PCR was then initiated using Bio-Rad CFX Connect™ Real Time 
System PCR machine. The following program was used: 
- Cycle 1: (1x) Initial denaturation 95C°, 3min 
- Cycle 2: (40x) Amplification 95C°, 15sec; 60C°, 1min; 
- Cycle 3: (1x) 8C° - ∞ 
 
Having two technical replicates allows exclusion of technical inaccuracies. Every pair was 
compared to confirm that the difference in CT values did not exceed 0.5. PCR results were 
analyzed using CFX Manager™ Software. Expression levels of YARS - a control “house-
keeping” gene, believed to be universally expressed in different cell lines, were used to 
normalize the expression of the genes of interest in the samples. Within the sample groups, 
relative expression was established by normalizing to an untreated control sample.  
Flow cytometry 
Flow cytometry is a method for molecular analysis of the single cells in suspension. It allows 
detection and quantification of biomarkers as well as separation of cell subpopulations 
based on set parameters. In a flow cytometer, a cell suspension is hydrodynamically focused 
into a one-cell wide stream of fluid which passes through a set of lasers. The extent to which 
the light is diffracted when passing through a cell reflects its size and granularity. These data 
are shown as forward and side scatter (figure 2.6). Lasers of different frequencies excite 
different fluorochromes producing a quantitative estimate of the fluorescent labeling on 
each cell. 
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Figure 2.6 Illustration of cell gating strategy used in flow-cytometric analysis. A. Forward scatter vs side scatter 
gating defines the main cell population (P1) and excludes cell debris. B. Side scatter width vs side scatter area 
defines the single cell population (P2) and excludes duplets.  
All of the analyzed parameters including size, granularity and the presence or absence of 
fluorescent labeling allow defining cell populations of interest using gating strategy. Using 
gating on the forward scatter versus side scatter makes it possible to exclude debris and 
most of the dead cells including only the main cell population for further analysis. Gating on 
the side scatter width versus side scatter area allows analysis of only single cells excluding 
duplets from the subsequent steps (figure 2.10). In the present study, flow cytometry has 
been used for detection of intracellular phosphoproteins, fluorescent dye transfer and cell 
cycle analysis.  
 
Phospho-S6 detection by flow-cytometry 
To prepare samples for intracellular flow cytometry, cells were grown as mono-cultures or 
co-cultures to full confluence in T25 cell culture flasks (table 2.7).  
 
 Melmet5 HM8 WI-38 
mono-culture 500 000 500 000 - 
co-culture 250 000 250 000 250 000 
Table 2.7 Cell numbers used for seeding for flow-cytometry analysis 
A B 
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In samples treated with Vemurafenib, 1µM final drug concentration was used. The drug was 
applied one day after cell seeding followed by the 24-hour incubation. All cells were 
detached using trypsin-EDTA, centrifuged and resuspended in 1:20 solution of 32% 
paraformaldehyde (PFA) and PBS. After 5min incubation at room temperature, the samples 
were centrifuged one more time and resuspended in 100% ice-cold methanol. Samples for 
phospho-S6 detection were stored at -80C° while samples for cell cycle analysis were stored 
at -20C°.  
 
 
 
Figure 2.7 Sample preparation in intracellular flow cytometry. Ab – antibody, Abs – antibodies. 
1. Samples were centrifuged at 2000rpm for 5min and resuspended in 1ml of PBS with 
1%BSA to remove methanol.  
2. Four samples from mono- and co-cultures with and without drug treatment, were 
then “barcoded” (as illustrated in figure 2.7) – labeled with a certain concentration of 
an unspecific, cell-binding fluorescent dye, pacific orange. This way, each cell from a 
sample carried a fluorescent tag, the intensity of which identified the sample. The 
cells were incubated with 5µl of pacific orange solution in four different 
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concentrations (0; 0.04ng/µl; 0.2ng/µl; 2ng/µl) for 30min at room temperature in the 
dark, centrifuged and resuspended in 1ml of PBS with 1%BSA.  
3. “Barcoded” cells from four samples were placed into a tube containing fluorescently-
labelled antibodies (Abs). In addition, the samples were added to a tube with no Abs 
for control.  
4. After 30min incubation in the dark with the Abs, all samples were centrifuged and 
resuspended in 400µl of PBS with 1% BSA, filtered through a 35µm nylon mesh and 
analyzed on a BD LSRII flow-cytometer identifying the level of the Ab-binding 
phospho-S6 in each sample. 
 
Dye transfer analysis 
To determine whether the cancer cells and the stromal cells interact via direct connections, 
namely, intercellular gap-junctions, we analyzed how a small fluorescent dye, calcein, is 
exchanged between these two cell populations. Melanoma cells were labeled with calcein, 
fluorescent in green, while WI-38 fibroblasts were labeled with gap-junction impermeable 
DiL, fluorescent in red. The labeled cancer cells and fibroblasts were mixed and seeded into a 
6-well plate overnight in a very dense co-culture. If the gap junctions were indeed present, 
calcein was transferred from cancer cells into the stromal cells, creating a double-positive 
population of fibroblasts, which could be identified by flow-cytometry. To verify the 
presence of gap-junctions, a gap-junction inhibitor, Carbenoxolone (CBX) was used to 
selectively block dye transfer (figure 2.8). 
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Figure 2.8 Dye transfer experiment scheme 
For this analysis, 2mln cancer cells and 2mln WI-38 fibroblasts were labeled separately with 
5µM fluorescent green calcein and 2,65µg/ml fluorescent red DiL respectively for 30min in 
the dark at 37C°. After repeated centrifugation to remove residual dye, 500 000 cells of each 
cell type were co-cultured in 6-well plates overnight to allow gap-junction formation. 500 
000 of WI-38 stained with DiL and 500 000 of either Melmet5 or HM8 cancer cells stained 
with calcein were also seeded out separately in the same plate for gating control. 50µM 
freshly prepared Carbenoxolone was added to co-cultures when seeding for gap junction 
inhibition. 
All samples were detached with trypsin-EDTA, washed with PBS and resuspended in 400µl of 
PBS with 1% BSA directly before the flow cytometry analysis.  
Cell cycle analysis 
To evaluate the DCA effect on Melmet5 and HM8 cells when cultured alone or with the WI-
38 fibroblasts, cell cycle status of the cancer cells following the treatment was analyzedby 
flow cytometry. Melanoma cells and fibroblasts were plated into T25 cell culture flasks using 
1:5 ratio, and incubated for 3 days to induce stroma-mediated phenotypic changes in the 
cancer cells. The cell cultures were then treated with 10mM and 30mM final dose of DCA for 
48 hours. All samples were detached with trypsin-EDTA, washed with PBS and fixed with 
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100% ice-cold methanol in -20C° for at least 20min. The samples were then centrifuged to 
remove methanol, washed with PBS and resuspended in 400µl of PBS containing 0.15µl/1ml 
Hoechst 33258 for fixed cells. Hoechst 33258, fluorescent in blue, binds to DNA. The 
intensity of the signal acquired from a Hoechst-labelled cell depends on the total DNA 
amount and allows distinguishing cells that are undergoing G1/G0, S phase or G2/mitosis 
stage of the cell cycle. After 30min incubation at 37C° in the dark, the samples were filtered 
through a 35µm nylon mesh and analyzed.  
Seahorse® metabolic analysis 
 
 
Seahorse® metabolism analyzers are designed to measure metabolic activity of the cells in 
vitro in normal culture conditions and under chemically induced stresses.  
The Seahorse® analyzers measure oxygen concentration and pH of the media with sensitive 
fluorescence probes in close proximity to adherent cells in vitro. The results are presented as 
oxygen consumption rate (pmol O2/min) (OCR) and exctracellular acidification rate 
(mpH/min) (ECAR). Each parameter reflects the extent to which the cells are utilizing either 
of the ATP-producing pathways: oxidative phosphorylation (OxPhos) taking place in the 
mitochondria or glycolysis in the cytoplasm. Oxygen is consumed in OxPhos, while glycolysis 
results in production and secretion of lactate into the media and decrease in pH.  
 
Figure 2.9 The Seahorse® 
equipment used in the current 
study: an XFe 96 and an XFe 24 
analyzer which were used with 
96- and 24-well cell culture 
plates respectively. (picture 
adapted from 
http://www.seahorsebio.
com/) 
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The measurement is done when a cartridge which carries the fluorescent probes is lowered 
into the cell culture plate inside the machine and hangs only 7µm above the cells. The 
fluorescent probes are then excited and the emitted signal is recorded and interpreted by 
the software. In addition to measuring normal OCR and ECAR, seahorse analyzers offer a 
possibility to stress the cellular metabolic pathways with chemicals injected at predefined 
intervals of time into the media from 4 injection ports. Injected chemicals as well as oxygen 
are distributed evenly in the media when the probes move up and down between the 
measurements.  
 
 
 
Both OCR and ECAR are measured in every well of the plate making it possible to compare 
these two parameters and detect the “metabolic switch” – shift in the preference of either 
glycolysis or OxPhos under certain conditions.  
 
 
Figure 2.10 Cartridge with sensitive probes comes in close proximity with the cells in the culture 
plate (picture adapted from http://www.seahorsebio.com/). 
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Media preparation for the analysis 
Non-buffered DMEM medium with no supplements is used for the Seahorse® assays. On the 
day of the analysis, the medium is warmed up to 37C° and supplemented with appropriate 
nutrients (table 2.8) depending the stress-test that is being performed (described below). 
The pH is then measured and adjusted to 7.4. The medium is filtered through a 0.22µM filter 
before being applied to the cells.  
 
 Final Concentration 
Mito-stress test  
Glucose 10mM 
Pyruvate 1mM 
L-Glutamine 2mM 
Glyco-stress test  
L-Glutamine 2mM 
 
 
Figure 2.11 OCR versus ECAR shows metabolic 
preference of a cell population (picture 
adapted from 
http://www.seahorsebio.com/). 
 
Table 2.8 Final concentrations of the nutrients 
added to the medium prior to analysis 
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Evaluation of ECAR and OCR in response to metabolic stress 
Seahorse® provides two stress kits which contain a set of drugs most suitable for stressing a 
particular metabolic pathway: a mito-stress kit and a glycolysis stress kit. Each kit contains 
three drugs. 
 
 
Mito-stress kit 
The mito-stress kit consists of chemicals which inhibit the functions of the main components 
of the mitochondrial electron transport chain. This makes it possible to establish cellular 
stress responses and define a set of metabolic parameters (figure 2.12).  
The standard setup usually includes measurements under “basal” conditions in pH-adjusted 
media supplemented with glucose, glutamine and pyruvate. The first injection then 
introduces oligomycin at an optimized concentration. Oligomycin inhibits ATP-synthase, 
greatly decreasing OCR. Second injection contains uncoupler FCCP at a cell-line specific 
concentration. Uncoupling of the electron transport chain leads to the leakage of protons 
from the intermembrane space of the mitochondria into the matrix and rapid reduction of 
oxygen. FCCP triggers dramatic increase in oxygen uptake and OCR. Finally, the third 
injection is a mixture of rotenone and antimycin which inhibit the first and the third 
complexes of the electron-transport chain respectively. As a result, the OCR is decreased to a 
minimum.  
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Glycolysis-stress kit 
The glycolysis stress kit is designed to create perturbations of cellular glycolysis system and 
determine basal and maximal rate of glycolysis of the cells. At the start of the test, the 
growth media is replaced with non-buffered DMEM medium supplemented with 2mM L-
Glutamine, but no other nutrients (see table 2.8). After one hour incubation in such 
conditions cells exhaust their reserves and therefore the starting levels of ECAR are very low. 
The first injection introduces glucose into media which immediately increases ECAR. The 
second injection contains Oligomycin at the same concentration as in the mito-stress test. 
The resulting decrease in OCR leads to increased ECAR as a compensation mechanism which 
keeps the ATP production at a stable level. ECAR after oligomycin injection shows glycolytic 
Figure 2.12 OCR in a mito-stress test. The first 3 measurements show OCR levels in normal 
conditions. Oligomycin decreases OCR revealing how much of the consumed oxygen is used for ATP 
production. FCCP increases OCR to the maximal level demonstrating maximal respiration rates. The 
difference between Maximal and basal respiration is defined as spare respiratory capacity. Rotenone 
an antimycin decrease OCR to the level of non-mitochondria-derived OCR. The difference between 
that level and the decrease after oligomycin injection shows proton leak.  
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capacity while the difference with the basal glycolysis level reveals glycolytic reserve. The 
last injection introduces 2-deoxyglucose which competes with glucose molecules for the first 
enzyme of the glycolytic pathway – glucose hexokinase. As a result, ECAR is brought down to 
the minimal level of non-glycolytic acidification.  
 
  
 
 
Experimental work flow 
Melmet5 were seeded in the Seahorse® plates in normal growth medium (table 2.9). 
 
XFe24 
2 day 
incubation 
XFe96; 
1 day 
incubation 
XFe96; 
2 day 
incubation 
Melmet5 
10000 - 
20000 
10000 - 
12000 
7000 
 
Figure 2.13 ECAR in glycolysis-stress test. Injection of glucose shows basal rate of glycolysis in 
absence of glutamine and pyruvate as media supplements. Oligomycin diverts cells towards glycolysis 
further increasing the ECAR. 2-deoxyglucose reduces ECAR to the minimal level demonstrating 
ECAR’s dependence on glycolytic pathway and verifies non-glucose-derived ECAR. 
Table 2.9 Cell numbers used 
for seeding in metabolism 
assays.  
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Vemurafenib was added to the cells 1 day after seeding at 1µM and 4µM concentration for 
24-hour incubation. For several experiments, fibroblast-derived factor rs100A4 was used to 
modulate metabolism of the Melmet5 cells. rs100A4 added to the cells 1 day after seeding 
at 2µg/ml for 48-hour incubation. 1 hour prior to analysis, the media was replaced with non-
buffered DMEM medium with adjusted pH. Medium used for the mito-stress test was 
supplemented with glucose, pyruvate and glutamine, while medium used in the glyco-stress 
test did not have supplements. For two of the tests on the XFe24 analyzer, non-buffered 
RPMI medium was used as it was much better tolerated by the cells. However, the results 
produced with the use of the two different media were very similar.  
Drug solutions were loaded into the injection ports of the cartridge at the following 
concentrations (table 2.10): 
 
 Final Concentration  
Oligomycin 1µM 
FCCP 0.5 µM 
Antimycin 1 µM 
Rotenone 1 µM 
Glucose 10mM 
2-deoxyglucose 100mM 
DCA 10mM 
 
Optimal FCCP concentration and cell density were optimized following the guidelines 
provided by Seahorse® in separate experiments.  
 
Table 2.10 Final concentrations of injected 
drug solutions. DCA was applied in the first 
injection in some of the experiments.  
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Normalization 
In 96-well plates 
After analysis was completed, cell number was estimated for normalization using a double-
stranded DNA intercalating fluorescent dye, pico-green. All medium was removed from the 
plates and replaced with 50µl per well of 4.12µl/ml solution of pico-green in TE buffer. The 
plates were then incubated for 30min at 37C° and the signal was measured in a plate reader 
using excitation of 485nm and emission of 528nm. 
In 24-well plates 
After the analysis was completed, cell number was estimated for normalization by 
measuring total protein amount. Medium was removed immediately after the end of the 
test. The plate was then rapidly frozen in -80C°. After thawing, cells were lyzed in each well 
with a mixture of lysis buffer and protease inhibitor. After 30min incubation on ice, samples 
were collected by vigorous pipetting and centrifuged for 15min. The protein concentration in 
the supernatant was assessed by nano-drop analyzer.  
Figure 2.14 Experimental work flow in Seahorse® metabolism essays  
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Results 
1. Generation of the GFP-luc labeled melanoma cell lines. 
Previously in the group, the effect of stromal cells on vemurafenib respose was investigated 
in one melanoma cell line, Melmet5 (figure 1.7). To expand the panel of cell lines, three 
additional melanoma cell lines, HM8, HM19 and Patient-3-pre were genetically modified to 
stably express green fluorescent protein (GFP) and luciferase (Melmet5 was modified 
previosuly in the group). Luciferase allowed evaluation of the melanoma cell viability in co-
culture with the non-labeled WI-38 fibroblasts. GFP expression made it possible to separate 
melanoma cells from the stromal cells in flow-cytometric studies and to purify them using 
fluorescence-activated cell sorting (FACS) for further analysis.  
Stable expression of GFP-luciferase fusion protein (GFP-luc) was achived by lentiviral 
transduction of melanoma cells as described in materials and methods. Subsequently, the 
cells with the strongest expression of GFP-luc were sorted by FACS (figure 3.1, A) and used to 
establish the cell cultures (figure 3.1, B). 
A                              B 
 
 
 
 
 
 
 
Figure 3.1 FACS of the GFP-positive melanoma cells. A. HM8 green positive cells (gated), separated from GFP-
negative cells based on fluorescence intensity. B. Overlaid phase contrast and green fluorescent pictures of the 
four GFP-luc labeled melanoma cell lines involved in the study.  
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2. Lung fibroblasts reduce sensitivity to vemurafenib in melanoma 
cells 
In the present study, 3 different culturing systems were used to explore the effect of lung 
fibroblasts on melanoma cell response to vemurafenib. 1) contact-based co-cultures, where 
melanoma cells and the fibroblasts were able to adhere to each other and establish cell-cell 
contacts; 2) trans-well inserts, where melanoma cells in the inserts were separated from the 
fibroblasts by a semi-permeable membrane, limiting interactions to soluble factor exchange; 
3) conditioned media, which was collected from the densely populated culture flasks with 
fibroblasts, filtered and applied to the melanoma cells in combination with vemurafenib.  
 
Co-cultures with fibroblasts are less sensitive to vemurafenib 
All of the melanoma cell lines involved in the current study carry a BRAFV600E mutation 
which makes them sensitive to BRAF inhibition. In order to investigate whether the presence 
of stromal cells alters melanoma cells’ response to vemurafenib, the cancer cells were grown 
either in mono-cultures or co-cultures with the WI-38 fibroblasts and treated with increasing 
doses of vemurafenib. As shown in figure 3.2, in all of the melanoma mono-cultures, the 
viability was strongly decreased after 72 hours of vemurafenib treatment. However, in co-
cultures, the viability of the cancer cells was higher, reflecting their lower sensitivity to the 
drug. This indicates that the fibroblasts induce partial protection of the melanoma cells 
against targeted therapy. This was particularly obvious in the HM8 cell line where the 
presence of fibroblasts almost completely abolished effects of the vemurafenib treatment.  
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Figure 3.2 Viability of the melanoma cell lines in mono-cultures or co-cultures with the WI-38 fibroblasts after 
72h treatment with vemurafenib as measured by the bioluminescence assay. Error bars represent SEM from 
three independent experiments. Significant at 0,5 and 2µM doses, p≤0.05 in all, apart from HM19, where 
p=0.1; unpaired t-test. 
Absence of the tumor-stroma cell contacts eliminates protection against 
vemurafenib 
To investigate whether a similar protection effect could be observed in the absence of direct 
contacts between tumor and stromal cells, we used the trans-well culturing system with 
inserts. A permeable membrane eliminates direct connections between melanoma and 
stromal cells, however, the 0.4µM large pores allow free exchange of the medium and 
secreted growth factors. We selected two melanoma cell lines for this analysis: Melmet5 and 
HM8. After 72h incubation with different doses of vemurafenib, both Melmet5 and HM8 
showed almost no difference in viability between wells that did and did not contain 
fibroblasts (figure 3.6). This indicates that the partial protection, which we have observed 
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previously in co-cultures, relies heavily on cell-cell contacts between the tumor and the 
stromal cells. 
  
Figure 3.3 Viability of the Melmet5 and HM8 cells in the inserts of the transwell-plates after 72h treatment 
with vemurafenib measured by the MTS assay. The bottom wells contained either respective melanoma cells 
(without WI-38) or the WI-38 fibroblasts (with WI-38). Error bars represent SEM from 4 independent 
experiments. Non-significant in all doses; unpaired t-test. 
 
Fibroblast-conditioned media (CM) induced partial protection 
It has been shown that the fibroblast-derived soluble factors in the medium elicit protection 
of melanoma cells against vemurafenib [45]. We verified those findings in our system by 
treating mono-cultures of the HM8 cells with vemurafenib in 1:1 diluted CM collected from a 
densely populated flask with WI-38 fibroblasts. We consider that such CM contains highly 
concentrated fibroblast-derived soluble factors. Fresh RPMI and HM8-conditioned media 
were used as controls. 72h treatment resulted in higher viability of the HM8 cells which have 
received WI-38 conditioned medium compared to the controls (figure 3.4). However, the 
resulting viability of approximately 50% was lower than observed in the contact-based co-
cultures, where the viability was close to 100% (figure 3.2).  
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Figure 3.4 Viability of the HM8 cells after 72h treatment with 2µM vemurafenib in the conditioned medium 
(CM) from WI-38 fibroblasts or HM8 diluted 1:1 with the RPMI growth medium in which the HM8 cells had 
been seeded. Fresh RPMI medium was used for control. Error bars represent SEM from three individual 
experiments. *- significant, p=0.04; unpaired t-test. 
3. Biological mechanisms involved in the fibroblast-mediated 
protection against vemurafenib 
The role of HGF-c-Met signaling  
The first published study that reported fibroblast-mediated protection from vemurafenib, 
revealed the role of HGF, secreted by the fibroblasts, that stimulates the c-Met receptor on 
the melanoma cells [45]. We therefore investigated whether cMet signaling is potentiated in 
Melmet5 and HM8 cells upon their interaction with the fibroblasts. For a positive control, we 
stimulated the MDA-MB-231 breast cancer cells, which are known to express the c-Met 
receptor [83], with recombinant HGF. We were able to see weak phosphorylation of the c-
Met in the MDA-MB-231 cells in response to HGF (figure 3.4 A, red arrow). In Melmet5 and 
HM8 cells, however, no visible bands corresponding to the phospho-cMet were present 
either with or without HGF stimulation (figure 3.4 A). Analysis of the Melmet5 and HM8 cells 
collected from the inserts, in which they were exposed to the fibroblast-secreted factors 
with and without vemurafenib, did not show an increase in phospho-cMET. On the contrary, 
the phospho-cMET bands seemed to be weaker in the samples where the fibroblasts were 
present (Figure 3.4 B), although the intensity of the bands was very low. These results do not 
conclusively demonstrate c-Met receptor activation in the melanoma cells in response to the 
HGF or the fibroblast-derived soluble factors under tested conditions.  
* 
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Figure 3.4 Phosphorylation of the c-Met receptor in Melmet5 and HM8 in response to either A) HGF, or B) WI-
38 derived soluble factors. Breast cancer cell line (MDA-MB-231 stimulated with HGF was used as a positive 
control (red arrows). A. The level of phospho-c-Met after 10min treatment with 100ng/ml HGF following 28h 
starvation with serum-free medium. B. The level of phospho-c-Met in HM8 and Melmet5 cells collected from 
the inserts of the transwell-plates containing either WI-38 fibroblasts or the respective melanoma cells in the 
bottom well and cultured for 48h. 1µM vemurafenib was applied for 24h.  
Fibroblasts activate the mTORC1-regulated pathway in melanoma cells via cell-
cell contacts 
Activation status of the mTORC1 pathway has been shown to predict response of the 
melanoma cells to vemurafenib. It was reported that mTORC1 is inactive in the melanoma 
cells which have a strong response, while resistant cells keep mTORC1 active despite the 
treatment with vemurafenib [55]. To explore the mTORC1 status in melanoma cells cultured 
with and without the fibroblasts we measured the level of phosphorylated ribosomal protein 
S6 (pS6) that is positively regulated by mTORC1 using flow-cytometry. As shown previously 
in the group (see figure 3.5), the level of pS6 was significantly reduced after treatment with 
vemurafenib in both Melmet 5 and HM8 mono-cultures, but not in co-cultures, where the 
pS6 level was significantly higher. As seen from figure 3.5 A (produced by Vasiliauskaite K.), 
A 
MDA-MB-231 
B 
MDA-MB-231 
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in the treated monocultures, the peak corresponding to pS6 level shifted to the left 
compared to the peak representing the non-treated cells. In the treated co-cultures, 
however, there were two melanoma cell subpopulations (two peaks in pink filled histogram): 
those with the reduced level of pS6 and those that maintained high level of pS6. In the 
Melmet 5 and HM8 cells collected from the inserts, however, the level of phospho-S6 was 
significantly reduced in all treated melanoma cells, despite the presence of fibroblasts 
(figure 3.5 B). This can be seen from the two overlapping peaks (filled histograms, clearly 
shifted to the left from the non-treated controls) representing the pS6 levels in the treated 
melanoma cells with and without the fibroblasts in the bottom. (figure 3.5 B). This was 
confirmed by western blotting (figure 3.5 C), where the intensity of the pS6 bands was 
equally low in all treated samples compared to non-treated controls. We also analyzed the 
levels of phospho-ERK, a downstream kinase of the MAPK pathway. As expected, ERK 
phosphorylation was reduced in the treated samples. Interestingly, the presence of 
fibroblasts in the untreated samples led to the reduction in pERK compared to the control 
sample. This was not further investigated.  
Taken together, these findings indicate that in absence of the direct cell-cell contacts with 
the fibroblasts, the level of pS6/mTORC1 activity is reduced by vemurafenib. In contrast, in 
the contact-based co-cultures, the level of pS6/mTORC1 activity remains high in a big 
fraction of cells. This further compliments the observation that the cell-cell contacts have a 
more pronounced influence on the melanoma cells with respect to the mTORC1 pathway 
than the soluble factors.  
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A 
Figure 3.5 The level of phospho-S6 and 
phospho-ERK in HM8 and Melmet5 cells A. 
pS6 levels in Melmet5 in mono- and co-
culture analyzed by flow-cytometry 
(experiment performed by Vasiliauskaite K.) 
B. Flow-cytometry analysis of the phospho-
S6 levels in Melmet5 and HM8 cells, 
collected from the inserts of the trans-well 
plates after 24h treatment with 1µM 
vemurafenib. The bottom well of the plates 
contained either the WI-38 fibroblasts or the 
respective melanoma cells. Histograms 
indicate pS6 level normalized to cell count. 
C. Western blot analysis of the Melmet5 and 
HM8 cells collected from inserts after 24h 
treatment with 1µM vemurafenib. 
 
 
B 
C 
Melmet5 HM8 
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The role of mTORC1 in the stroma-mediated protection 
To validate involvement of the mTORC1 in the stromal protection, we applied an mTORC1 
inhibitor, everolimus, together with vemurafenib and measured the viability of the 
melanoma cells in mono- and co-cultures. As shown in figure 3.5, the protection induced by 
the stromal cells (highlighted with red lines next to the bars) was either reduced (in HM8 and 
Patient-3-pre cells) or completely abolished (in Melmet5 and HM19 cells) when vemurafenib 
was used in combination with everolimus. This demonstrates that mTORC1 suppression 
combined with vemurafenib treatment, reduces melanoma cell survival.  
 
Figure 3.6 Viability of the four melanoma cell lines in mono-cultures versus co-cultures with WI-38 fibroblasts 
after 72h treatment with either 2µM vemurafenib (Vem), 5nM everolimus (20nM for Melmet5) (Ev), or a 
combination (Vem + Ev), measured by the bioluminescence assay. The red lines show the fibroblast-mediated 
protection effect, i.e. difference in viability of the melanoma cells in co-cultures compared to the mono-
cultures. Error bars indicate standard deviations from 3 technical replicates in a single experiment. 
Melanoma cells adhere to the fibroblasts in co-culture 
Given the importance of direct cell-cell contacts for stromal protection, we characterized the 
capacity of the four melanoma cell lines to adhere to fibroblasts. In order to analyze this, we 
added melanoma cells to the confluent layer of fibroblasts, incubated them for 1h, washed 
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away non-adherent melanoma cells and scored the adherent fraction. We observed that 60 
to 90% of the melanoma cells were adherent to the fibroblasts (figure 3.7), which shows that 
the melanoma cells are able to attach to the lung fibroblasts. The adhesion capacity, 
however, did not correlate with the stromal protection efficacy seen in figure 3.2. 
 
Figure 3.7 Attachment of the melanoma cells to the WI-38 fibroblast monolayer after 1h incubation as 
measured by the bioluminescence assay. Error bars represent standard deviation from 6 technical parallels in a 
single experiment. 
The role of gap-junctions in the stroma-induced protection 
The observation that the melanoma cells physically interact with fibroblasts via adhesion 
prompted further investigation into the role of the intercellular connections, specifically gap 
junctions that have been previously linked to SMDR [20]. Here we investigated whether gap-
junctions contribute to the communication between melanoma cells and the WI-38 
fibroblasts. First, we tested whether the Melmet5 and HM8 cells establish gap-junction 
connections to the fibroblasts in co-culture, using the dye-transfer method. We stained the 
melanoma cells and the fibroblasts with two different fluorescent dyes – calcein, fluorescent 
in green, and Dil, fluorescent in red. We then incubated the cancer cells together with the 
fibroblasts overnight and observed transfer of the gap-junction permeable calcein from 
melanoma cells to the fibroblasts by flow-cytometry. The presence of gap junctions was 
demonstrated by a population of red fibroblasts which gained green colour i.e. was double 
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positive. Both Melmet5 and HM8 showed a degree of dye transfer (figure 3.8), however it 
was a lot more pronounced in the co-culture with HM8 cells, rather than Melmet5, as can be 
seen from a large population of green fibroblasts in the case of HM8 (figure 3.8) 
 
 
Figure 3.8 Evidence of gap junctions between fibroblasts and melanoma cells. Dot blots illustrating dye transfer 
from calcein-labeled melanoma cells (green dots) to Dil-stained fibroblasts (red dots) after over-night co-
incubation. Left panel: Overlay of the separately stained and incubated melanoma cells with high calcein 
intensity (green) and fibroblasts with high Dil intensity (red), used for setting the gates. Right panel: transfer of 
calcein from the melanoma cells resulted in a shift of the red fibroblast population to the right, indicating the 
presence of double-positive cells (black arrows).  
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Having found evidence of gap-junctions between the melanoma cells and the fibroblasts, we 
next attempted to block them using two available gap-junction inhibitors – carbenoxolone 
(CBX) and chlordane. We tested them to find out the dose which does not impair cell 
viability. Both inhibitors showed little to no toxicity in small doses (figure 3.9 A). We chose to 
proceed with 50µM CBX in order to block gap-junctions. To validate CBX effect on gap 
junction inhibition, we cultured calcein-labeled melanoma cells with the red fibroblast as 
described above, in the presence of CBX. Comparing the size of the double-positive 
population of fibroblasts with and without the CBX, we found a considerable reduction after 
incubation with both Melmet5 and HM8. This can be seen from comparison of green and red 
histograms in figure 3.9 B), where a clear shift to the left in the presence of CBX was 
observed. However, gap junction inhibition was incomplete, since some of the fibroblasts 
retain calcein, i.e. some of the fibroblasts were double positive after inhibition with CBX. This 
can be seen in co-cultures with HM8 in particular, where cells treated with CBX (red peak) 
still had considerably stronger calcein intensity than in the control mono-cultures (black 
peak). 
Finally, we set out to examine whether the inhibition of gap-junctions with CBX would 
diminish the stroma-mediated protection in the melanoma co-cultures with the fibroblasts. 
We were unable to perform the experiment on Melmet5 cells due to technical difficulties. 
The difference in viability between HM8 cells in mono- versus co-cultures was unaffected by 
the presence of CBX, and the same stroma-induced protection was observed (figure 3.9 C). 
Taken together these data do not exclude a possibility that the melanoma cells and the 
fibroblasts communicate via gap-junctions. However, in a non-toxic concentration, gap 
junction inhibitor CBX failed to reduce the stoma-mediated protection. 
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Figure 3.9 Effect of gap-junction inhibition by CBX A. Viability of the Melmet5 and HM8 cells following 72h 
incubation with gap junction inhibitors 1) carbenoxolone (CBX) or 2) chlordane measured by the 
bioluminescence assay B. Dye-transfer inhibition by CBX demonstrated as a shift in the calcein intensity of the 
fibroblasts, where black peak represents control Dil-labeled cells in mono-culture; green peak represents 
fibroblasts in co-culture with no CBX; and red – fibroblasts in co-culture treated with CBX. C. Viability of the 
HM8 cells either in mono-culture or co-culture with the WI-38 fibroblasts after 72h treatment with 
vemurafenib with or without 50µM CBX measured using the bioluminescence assay. Error bars represent 
standard deviations from 5 technical parallels in a single experiment. 
A 
1 2 
B 
C 
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4. Fibroblasts modulate transcriptional phenotype in melanoma cells 
To evaluate how fibroblasts influence the molecular phenotype of the melanoma cells, we 
measured expression of genes previously shown to be associated with the so-called 
proliferative differentiated and invasive de-differentiated phenotype [46]. It has been 
recently discovered that the invasive phenotype (defined as MITFhigh/AXLlow) is associated 
with resistance to vemurafenib [57, 58]. Expression levels of DKK3, THBS1 and AXL, which 
encode the Dickkopf-related protein 3, Thrombospondin 1 and Tyrosine-protein kinase 
receptor respectively, were used as markers of the invasive i.e. resistant phenotype [56]. 
Conversely, expression of the melanocyte-specific transcription factor MITF-M and its 
targets MLANA and TYR, was used as a label of the differentiated i.e. vemurafenib sensitive 
phenotype.  
Melanoma cells derived from the co-cultures with fibroblasts and purified by FACS had 
decreased expression of the differentiation genes, particularly in Melmet 5 (figure 3.10 A). At 
the same time, the invasive signature genes were strongly up-regulated (figure 3.10 B).  
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Figure 3.10 Relative gene expression levels in Melmet5 (left panel) and HM8 (right panel) cells in mono- and co-
cultures, separated from fibroblasts by FACS, and analyzed by real time PCR. A. Relative expression of the 
melanocyte-specific differentiation genes in cancer cells derived from co-cultures compared to mono-cultures, 
where the expression levels were set to 1. B. Relative expression of the invasion-phenotype genes in melanoma 
cells derived from co-cultures compared to mono-cultures, where the expression levels were set to 1. Error 
bars in A and B represent standard error from three replicates. Significant in all Melmet5 samples and AXL in 
HM8. p≤0.01; unpaired t-test. 
 
For comparison, we measured expression levels of the same genes in the melanoma cells 
collected from the inserts with or without the fibroblasts in the bottom. As shown in the 
figure 3.11, the fibroblast-induced gene expression changes in the melanoma cells were 
minimal in the absence of cell-cell contacts. Together, these data indicate that the WI-38 
fibroblasts induce an invasive, de-differentiated phenotype in melanoma cells when cell-cell 
contacts are established. Fibroblast-derived soluble factors failed to induce such a 
phenotypic shift, which highlights the importance of cell-cell contacts in this context.  
A 
B 
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Figure 3.11 Relative gene expression levels in Melmet5 and HM8 cells collected from the inserts of the trans-
well plates. The bottom well contained either respective melanoma cells (without WI-38) or the fibroblasts 
(with WI-38). Gene expression was normalized to the expression in samples without WI-38.  
 
WI-38 fibroblasts alter expression of metabolism-related genes in melanoma cells 
via cell-cell contacts 
Given an association between invasive phenotype, MITF and glycolysis, as described in the 
literature, [67, 69], we aimed to determine whether contact based-co-culture with the WI-38 
fibroblasts modified expression of metabolism-associated genes. We evaluated the 
expression of PGC1α – the main regulator of mitochondrial activity in the cells, and LDHA – a 
critical enzyme involved in the final step of glycolysis. We observed that melanoma cells 
from the co-cultures strongly down-regulated PGC1α, while LDHA expression was up-
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regulated (figure3.12). Both Melmet5 and HM8 cells demonstrated minimal changes of 
PGC1α and LDHA after being cultured in the inserts, however. This indicates that the 
presence of fibroblasts induces alterations in the expression of metabolism-related genes in 
melanoma cells, but this largely relies on direct cell-cell contacts.  
 
 
Figure 3.12 Relative expression levels of PGC1α and LDHA genes in Melmet5 and HM8 as measured by real-
time PCR. Melmet5 and HM8 cells were cultured either as mono-cultures or co-cultures with the WI-38 
fibroblasts for 72h and then separated using FACS (labeled co-cultures). Melanoma cells collected from the 
inserts of the trans-well plates, which contained either respective melanoma cells (without WI-38), or WI-38 
fibroblasts (with WI-38) in the bottom well (labeled inserts). The error bars in the co-cultures group represent 
standard error from three independent experiments. *- significant. p≤0.05; unpaired t-test. 
 
* 
* 
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 5. Using DCA to target the melanoma cells with altered metabolism 
Changes in metabolism can be best studied by the Seahorse™ technology, which allows 
precise evaluation of the cellular metabolic activity in vitro in real time (see materials and 
methods for detailed protocol). It can be applied to the melanoma cells in order to establish 
their metabolic preference as well as reactions to various stimuli.  
 
DCA induces strong metabolic shift from glycolysis to OxPhos in Melmet5 
As we have observed previously, contact-based co-culture with the WI-38 fibroblasts 
induced invasive phenotype associated with increased expression of glycolysis-regulator 
LDHA in melanoma cells (figure 3.10). We proposed that this phenotypic switch makes the 
melanoma cells rely more heavily on glycolysis for ATP production, which may result in 
greater sensitivity to glycolysis inhibition. To test this, we employed DCA, which is a potent 
metabolic modulator that strongly up-regulates the use of the OxPhos pathway by blocking 
its inhibitor.  
First, we validated the DCA effect on melanoma cell metabolism. To this end we acutely 
treated the Melmet5 cells with DCA and scored OCR and ECAR using the Seahorse™ 
technology. DCA injection led to a rapid increase of oxygen consumption (figure 3.19 A) 
while simultaneously down-regulating aerobic glycolysis as measured by the extracellular 
acidification rate (figure 3.13 B).  
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Figure 3.13 DCA treatment modulates metabolic profile of Melmet5. A. ECAR prior to and after the DCA 
injection. Graph from a representative experiment. B. ECAR in Melmet5 after acute treatment with 10mM DCA 
compared to the basal ECAR. C. OCR prior to and after the DCA injection. Graph from a representative 
experiment. D. OCR in Melmet5 after acute treatment with 10mM DCA compared to the basal respiration rate. 
The data were normalized to the basal respiration rate of control sample which was set as 100%. In A and C the 
error bars stand for standard deviations in 4 technical parallels. In B and D the error bars represent SEM in 4 
separate experiments. *- significant. p≤0.0005; unpaired t-test. 
 
Next, we cultured the melanoma cells alone and together with the WI-38 fibroblasts for a 
period of 72 hours to induce the stroma-mediated phenotypic switch. We then treated the 
cultures with increasing doses of DCA for 48 hours. HM8 cells did not demonstrate any 
differences in viability between mono- and co-cultures under these conditions. The Melmet5 
A B 
C D 
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cells, however, showed a dramatic difference where the viability in co-cultures was greatly 
reduced (figure 3.14). 
 
 
 
Figure 3.14 Viability of the HM8 and Melmet5 cells in mono-cultures or co-cultures with WI-38 fibroblasts after 
72h followed by 48h of treatment with DCA measured by the bioluminescence assay. Error bars represent SEM 
from the four separate experiments. Significant in Melmet5, both doses. p=0.001; unpaired t-test. 
 
We further verified increased sensitivity of cells in co-culture to DCA by analyzing cell cycle 
progression in Melmet5 and HM8. The cells were cultured for 72 hours prior to the 48hrs-
DCA treatment, when the cells were collected, stained with the DNA-binding dye Hoechst 
33258 and analyzed by flow cytometry. We found that in Melmet5, DCA treatment induced 
cell cycle arrest at G2 phase, which was more pronounced in co-cultures than in mono-
cultures (figure 3.15). We performed three separate experiments which showed a similar 
trend, however here we include the one in which the difference was the strongest. This 
verifies that melanoma cells from co-cultures are more vulnerable to metabolic disruptions 
by DCA. 
 
 
 
HM8 Melmet5 
67 
 
 
 
Figure 3.15 Cell cycle analysis in the Melmet5 cells in mono- and co-culture treated with DCA. Cells were 
cultured for 72 hours before being treated with 30mM DCA for 48 hours. A. Cell cycle in the mono-cultures. B. 
Cell cycle in the co-cultures. Increase in the second peak corresponds to the cell cycle arrest, which is more 
evident in co-cultures. Bar graphs in A and B show fractions of the analyzed cells undergoing different stages of 
the cell cycle (data from the analyzed histograms). 
6. Vemurafenib and everolimus induce metabolic changes in the 
melanoma cells 
It has been shown by others that therapeutic agents influence cancer cell metabolism [67]. 
Based on that, we tried to evaluate changes in the energy metabolism triggered by 
vemurafenib and everolimus in the Melmet5 melanoma cells. 
A 
B 
68 
 
Vemurafenib treatment modifies expression of metabolism-related genes 
To explore how vemurafenib affects expression of metabolism-related genes, we measured 
expression of the previously mentioned PGC1α and LDHA in Melmet 5 and HM8. We 
discovered that in both cell lines, PGC1α expression was strongly up-regulated, suggesting 
increased preference of the OxPhos pathway in the vemurafenib treated cells. In contrast, 
expression of the LDHA was not significantly changed in either Melmet5 or HM8 cells (figure 
3.16).  
 
 
Figure 3.16 Expression levels of PGC1α and LDHA in Melmet5 and HM8 cells after 1µM Vemurafenib treatment 
for 24h. Error bars indicate standard errors from three parallels. *- significant. p=0.002; unpaired t-test. 
Vemurafenib decreased lactate production and oxygen consumption rates in the 
Melmet5 cells 
We further used Seahorse™ analyzers to test whether treatment with vemurafenib affects 
the metabolic functions – extracellular acidification rate (ECAR) and oxygen consumption 
rate (OCR), reflecting glycolytic and mitochondrial activity, respectively. Vemurafenib was 
applied for one day prior to the test and led to a decrease in basal ECAR, as well as ECAR 
after glyco-stress (described in materials s and methods) indicating down-regulation of the 
aerobic glycolysis (figure 3.17). The decrease in ECAR was not dose-dependent.  
 
 
* 
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Figure 3.17 Metabolic parameters reflecting glycolytic activity in Melmet5 cells with and without treatment 
with 1µM and 4µM vemurafenib for 24h. A. Graphs from a representative experiment showing changes in 
ECAR in the control and vemurafenib-treated Melmet5 cells during the glyco-stress test. Error bars stand for 
standard deviations from 6 technical replicates in the representative experiments. B. Basal ECAR. Error bars 
represent SEM in three separate experiments, normalized to the untreated control, which was set as 100%. *- 
significant. p≤0.005; unpaired t-test. 
 
 
In addition to triggering a reduction in aerobic glycolysis, vemurafenib also down-regulated 
basal OCR (figure 3.18 A, B), indicating a decrease of the mitochondrial activity. 
Vemurafenib-triggered reduction in both ECAR and OCR indicates an overall shift to a less 
metabolically active state. 
 
 
 
 
 
 
 
A B 
ECAR 
70 
 
 
 
 
 
 
 
 
Figure 3.18 Metabolic parameters reflecting mitochondrial activity in Melmet5 cells with and without 
treatment with 1µM and 4µM vemurafenib for 24h. A. Representative experiment showing changes in OCR in 
the control and vemurafenib-treated Melmet5 cells in response to the chemically induced mitochondrial stress. 
Error bars stand for standard deviations from 6 technical replicates in the representative experiment. B. Basal 
OCR prior to the oligomycin injection. Error bars represent SEM in three separate experiments, normalized to 
the untreated control, which was set as 100%. *- significant. p≤0.05; unpaired t-test. 
 
 
Despite the basal OCR reduction in Melmet5 cells (figure 3.18), the vemurafenib treatment 
resulted in a strong increase of the spare OCR, after addition of the uncoupler FCCP (figure 
3.19). This effect was reproduced in three independent experiments and may indicate that 
BRAF inhibition leads to increased ability to utilize the OxPhos pathway in the treated cells.  
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Figure 3.19 Vemurafenib treatment modulates spare respiration capacity in Melmet5. A. Data from the 
representative experiment (shown in figure 3.13), where the OCR values were normalized to the basal OCR in 
each sample. B. Spare respiration capacity after FCCP injection in Melmet5 treated with 1µM and 4µM 
vemurafenib for 24h. Error bars show SEM in three separate experiments. *- significant. p≤0.0005; unpaired t-
test. 
Everolimus effect on aerobic glycolysis and oxygen consumption in Melmet5 cells 
mTORC1 has been cited as a regulator of glycolysis in several contexts. However, its role in 
metabolic alterations in melanoma remains poorly understood. Here we investigated the 
effect of everolimus on oxygen consumption and lactate production in the Melmet5 cells. 
The cells were treated with 5nM everolimus for 24 hours prior to running the Seahorse™ 
assay. We found that OCR was reduced, similarly to the effect observed after treatment with 
vemurafenib. ECAR levels, however, were almost unchanged (figure 3.20), suggesting that 
everolimus has a stronger influence on mitochondrial activity than glycolysis. 
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Figure 3.20 Everolimus treatment modulates oxygen consumption rate in Melmet5. A. OCR in Melmet5, which 
were treated with 5nM everolimus for 24 hours prior to the test. B. OCR and ECAR basal levels (5
th 
measurement, prior to the injection of oligomycin) in the everolimus-treated samples compared to untreated 
controls. Data from 4 technical parallels in a single experiment. 
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Discussion 
Stroma-mediated vemurafenib resistance in melanoma 
Discovery of the targeted therapy against kinases of the MAPK pathway has been a huge 
step forward in the treatment of metastatic melanoma. However, MAPK inhibition, although 
efficient, is almost never long-lasting. Research in the field of malignant melanoma has since 
focused on the nature of the drug resistance and the role of the intricate cross-talk between 
the cancer cells and the microenvironment.  
Here we show that stromal fibroblasts potently protect melanoma cells from vemurafenib 
enhancing the survival of treated cancer cells. This goes in concert with several of the 
previous reports showing stromal role in protection against vemurafenib and other targeted 
agents [45, 84]. These studies have implicated stroma-secreted soluble factors in this 
protection. Confirming these findings, we show that concentrated conditioned media 
derived from the fibroblasts does elicit a degree of protection on the HM8 melanoma cells. 
However, direct proximity of the tumor and stromal cells appeared to be a more important 
requirement as the absence of the intercellular contacts almost completely abolished the 
protective effect. Supported by the evidence that adhesion to the other cells and the 
extracellular matrix is important for survival and proliferation, this finding pointed towards 
cell-cell connections as a possible mechanism for vemurafenib resistance. Cell contacts 
between the cancer and the stromal cells have been shown to be important for every step of 
the disease progression [19, 22, 23] and here we show that they continue to be important 
for cancer cell survival after treatment.  
The mechanism of the cell contact-mediated protection remains not fully understood, 
however. Gap junctions have been previously described as mediators of protection against 
chemothepary in melanoma brain metastasis [20, 21]. Here, we could not find the evidence 
of their involvement in our model system, though our data does not exclude this possibility 
completely. Other studies where inhibition of gap-junctions resulted in reduced SMDR, used 
higher concentrations of inhibitors (i.e. 100µM CBX [20, 21]), that in our hands were severely 
toxic for the melanoma and the stromal cells alike. We therefore had to use a smaller dose 
(50µM CBX) which induced only a partial gap-junction blockade. This might be the reason 
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why we could not see a reduction in the stroma-mediated protection. The other explanation 
is that the gap-junctions are not involved in SMDR, while other proteins, for instance 
integrins, coordinate pro-survival signaling between the stromal cells and the cancer cells 
enabling protection. Indeed, integrins and integrin-related signaling were shown to be 
involved in the tumor-stroma crosstalk [85]. A recent publication by Eishu Hirata and 
colleagues demonstrated that the fibroblast-mediated protection of the melanoma cells 
against vemurafenib is maintained via β1-integrins and that inhibition of β1-integrins 
abolishes such protection [86]. It would therefore be interesting to investigate the role of 
integrins in our model.   
Fibroblasts induce mTORC1 activation 
We found that in mono-cultures that are sensitive to vemurafenib, S6 phosphorylation was 
significantly reduced, suggesting diminished mTORC1 activity after the treatment. This 
corresponds to other studies which showed that the vemurafenib-sensitive cells suppress 
mTORC1 activation under the influence of vemurafenib treatment [55]. However, as others 
in the group have demonstrated, this suppression was significantly impaired in the co-
cultures, leading to higher levels of pS6 as a direct consequence of mTORC1 activity in the 
presence of fibroblasts. Here we also show that pS6 level remains low if the treatment is 
performed in the trans-well setup. Based on these results we propose that the stroma-
mediated protection is mediated through mTORC1 activation triggered by cell connections 
to the fibroblasts.  
There are multiple cascades, converging on mTORC1 [87], which functions as a sensor for 
diverse intracellular events. In the context of melanoma, mTORC1 activation may be induced 
by at least two upstream regulators: pERK, or an alternative PI3K-AKT signaling cascade. ERK 
phosphorylation has been linked to mTORC1 activation [88] and may therefore be the driver 
of this signaling in the cells influenced by the stroma. pERK, being a member of the MAPK 
pathway is normally inhibited by vemurafenib; however, as mentioned previously, it may be 
reactivated in the vemurafenib-resistant cells. At the same time, it is possible that mTORC1 
is activated by a different proliferation-related pathway involving PI3K and AKT. Previous 
studies implicate both mechanisms [88, 89], therefore it is important to further investigate 
their contributions in our model system. 
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The notion of mTORC1 involvement was further strengthened in the experiments where 
inhibition of mTORC1 by everolimus in presence of vemurafenib, reduced stroma-mediated 
protection. There are two possible explanations for this effect of the everolimus treatment. 
First, everolimus may eliminate melanoma cell subpopulation that does not respond to 
vemurafenib due to stromal influence. Secondly, everolimus may sensitize the cells to BRAF 
inhibition. Interestingly, in mono-cultures the cytotoxic influence of vemurafenib and 
combination of vemurafenib and everolimus, was the same, indicating that everolimus does 
not improve the vemurafenib effect in the sensitive population.  
Fibroblasts induce a phenotypic shift in melanoma in the contact-based cultures 
In this study we found that the presence of fibroblasts stimulates a phenotype shift towards 
a more aggressive transcriptional state. Fibroblasts stimulated expression of genes 
characteristic for invasive cells [46], namely AXL, DKK3 and TBS1. Expression of melanocytic 
lineage-specific genes, MITF and its targets, however, was reduced in co-cultures, consistent 
with the invasive, vemurafenib resistant phenotype. We did not detect strong differences in 
expression of those genes in the melanoma cells collected from the trans-well plates, once 
more proving that cell proximity/adhesion is required for the stroma to influence the cancer 
cells. This suggests that under the influence of fibroblasts, melanoma cells become more 
invasive and less differentiated. Furthermore, reduced MITF and elevated AXL expression, 
which indicates dedifferentiated and invasive phenotype, has recently been linked to 
vemurafenib insensitive state [57].  
These data show that the stromal cells potentiate vemurafenib resistant molecular 
phenotype in melanoma, likely via direct cell-cell connections. This implies that large area of 
contact with the stroma predicts low sensitivity to BRAF inhibition in melanoma and may 
therefore be predicative of the treatment outcome.  
The phenotypic shift is accompanied by the alterations in metabolism  
Rapidly proliferating melanoma cells tend to utilize aerobic glycolysis for ATP production. 
This is in part controlled by the down-regulation of MITF expression by the activated MAPK 
pathway. Low levels of MITF lead to reduced expression of PGC1α and, as a result, decrease 
of the mitochondrial activity and OxPhos [67]. Considering that low MITF levels are 
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characteristic of the resistant phenotype and that, as we have shown, the stromal cells 
encourage this phenotype, it is tempting to suggest that co-culture with the fibroblasts 
would stimulate a metabolic switch from OxPhos to aerobic glycolysis. Additionally, it is 
known that one of the mediators of glycolysis is the PI3K-mTORC1 pathway [90-93]. It is 
possible that mTORC1 activation induced by the stromal cells may also impact metabolism of 
the cancer cells and therefore contribute to the overall malignant phenotype. However, it 
appears that mTORC1 activation leads to either up- or down-regulation of aerobic glycolysis 
depending on the cell type and immediate conditions. Little is known about metabolism 
regulation by mTORC1 in melanoma. 
Unfortunately, testing this hypothesis is technically difficult as measuring lactate levels in co-
cultures would not make it possible to distinguish lactate produced by the cancer cells from 
lactate released by the stroma. However, we indirectly show the stroma-induced metabolic 
shift by analyzing the gene expression of the melanoma cells separated from fibroblasts by 
FACS. Melanoma cells from the contact-based co-cultures indeed had depleted PGC1α 
expression, while also showing increased LDHA, which is involved in glycolysis. Once again, 
we detected much weaker differences in the trans-well system where direct cell-cell 
contacts were not permitted. This suggests that the melanoma cells which come in close 
contact with the fibroblasts undergo transcriptional changes that might result in the shift of 
metabolic preference towards aerobic glycolysis. 
Furthermore, we evaluated effect of the vemurafenib and everolimus on OxPhos and lactate 
production using the Seahorse™ technology. We discovered a decrease of the oxygen 
consumption levels shortly after the treatment with either of the drugs, indicating 
suppressed metabolism. This is consistent with the fact that most drugs that reduce 
proliferative activity of the cells tend to also decrease their general metabolic activity which 
manifests itself in reduction of both lactate production and oxygen consumption. The 24-
hour treatment period that we have applied in this study may be insufficient for the long-
term compensation mechanisms to come into play. Regulation of aerobic glycolysis can be 
rather abrupt as it often involves attenuation of the enzymatic activity. However, up-
regulation of OxPhos calls for increased mitochondrial activity as well as simply more 
mitochondria, which may take several days. Given a longer treatment period, we may be 
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able to detect metabolic compensation by up-regulation of OxPhos after treatment with 
vemurafenib as demonstrated in several previous studies [67, 70]. 
Taking into account the possibility that stroma induces a metabolic shift, we argued that it 
may make the melanoma cells more vulnerable to dugs targeting preferred metabolic 
pathways. We hypothesized that melanoma cells exposed to the fibroblasts grow dependent 
on the aerobic glycolysis pathway which may make them more sensitive to the drugs that 
impact glycolysis and/or promote OxPhos. We tested this by using the OxPhos stimulant, 
DCA. We found a stronger reduction of cancer cell viability and cell cycle arrest in the G2 
phase in Melmet5 co-cultures compared to mono-cultures in response to DCA. The other cell 
line, HM8, however, showed no fibroblast-induced difference in either viability or the cell 
cycle progression, which correlates with a less prominent shift in the metabolism gene 
expression. It should be mentioned, however, that applied DCA doses induced cell toxicity in 
both melanoma cells and fibroblasts, highlighting the need for more specific and efficient 
metabolic modulators. 
Future perspectives  
Our data strongly support the idea that fibroblasts in the tumor tissue play an extremely 
important role, transforming the cancer cells through changes in their signaling, gene 
expression and metabolism. We also show that the tumor cells need to be physically close to 
the stromal cells for all of these changes to take place. In the future, it would be interesting 
to confirm the involvement of integrins in the fibroblast-induced protection in our model 
system. This would involve labeling these proteins to visualize connections between the 
cancer cells and the fibroblasts. If present, such connections can then be inhibited to verify 
their role in the SMDR. Additionally, our data did not fully eliminate the possibility of gap 
junctions being important for the fibroblast-induced protection. It would therefore be 
important to draw the final conclusion by using a more specific and less toxic gap-junction 
inhibitor, if possible.  
In addition, results of the current study indicate that efficacy of vemurafenib may be 
improved by combining it with inhibitors of stroma-induced alterations to tackle resistance. 
With a growing arsenal of inhibitors and small therapeutic agents available for research, 
there is an enormous potential for development of more appropriate and effective 
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treatment strategies. It would therefore be of particular interest to verify the in vitro data 
described here, in vivo and to find out whether our findings could have a potential for 
medical use. In particular, a combination of mTORC1 inhibitor everolimus, and vemurafenib, 
may lead to a better response and experiments where these two agents are applied 
together are currently being initiated on the mouse models.  
Finally, one of the least well understood questions raised in this study is the role of mTORC1 
in control of energy metabolism in the melanoma cells. Further experiments are necessary 
to draw conclusions on this subject. Specifically, the direct impact on metabolism by 
mTORC1 activation and inhibition in the melanoma cells has to be evaluated and it would be 
most convenient to use the Seahorse™ metabolic assays for that purpose. 
 
 
Conclusions 
• Fibroblasts induce partial protection of melanoma cells against treatment with 
vemurafenib. 
• The fibroblasts’ influence relies mainly on cell-cell contacts and/or proximity and is 
mediated through maintained activity of mTORC1 signaling.  
• Fibroblasts stimulate melanoma cells to undergo transcriptional reprogramming and 
acquire vemurafenib resistant phenotype accompanied by the altered expression of 
metabolism-related genes. 
• Altered energy metabolism in the melanoma cells may be exploited as a therapeutic 
target. 
• Vemurafenib and the mTORC1 inhibitor everolimus modulate melanoma cell 
metabolism and trigger an initial decrease in the metabolic activity. 
 
Further studies are required for better understanding of the precise mechanisms involved in 
the tumor-stroma interaction which reduces vemurafenib efficacy. 
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Supplementary Table 
Cell culturing Producer 
Catalogue 
number 
RPMI-1640 medium Sigma® Life Sciences R0883 
EMEM medium ATCC 30-2003 
L-alanyl-L-glutemine (Glutamax) Sigma® Life Sciences G8541 
Penicilin - streptavidin Sigma® Life Sciences P4458 
Fetal Bovine Serum (FBS)  Sigma® Life Sciences F7524 
Tissue culture EasY-flasks Nunc 157400 
Tissue culture plates Falcon® 353072 
24-well trans-well plates Corning® 3470 
6-well trans-well plates Corning® 3450 
Trypan-blue Stain (0.4%) Gibco life Technologies 15250-061 
Countess™automated cell counter Invitrogen  
Countess™ cell counting chamber slides Invitrogen C10283 
EDTA (0.02%) Sigma® Life Sciences E8008 
Trypsin - EDTA Sigma® Life Sciences T3924 
Dimethyl-sulphoxide-hybri-max (DMSO)  Sigma® Life Sciences D2650 
1420 multilabel counter Victor² Wallac  
PBS Sigma® Life Sciences D8537 
White wall 96-well plates for 
bioluminescence measurement 
Corning Costar 3610 
Therapeutic drugs Producer 
Catalogue 
number 
Vemurafenib Selleckchem S1267 
Everolimus Novartis  
Virus production Producer 
Catalogue 
number 
Optimem Gibco 31985 
Lipofectamine 2000 Life technologies 11668027 
293HEK cells ATCC CRL-1573 
Polybrene Sigma® Life Sciences AL-118 
Antibodies For Western blotting Producer 
Catalogue 
number 
α-tubulin, mouse monoclonal EMD Millipore, USA CP06 
phospho-cMet, rabbit monoclonal Cell Signaling 3077 
phospho-S6, rabbit monoclonal Cell Signaling 4858S 
phospho-ERK, p44/42 MAPK Cell Signaling 4370S 
Histone 3 Cell Signaling 4499S 
PGC1-α Cell signaling 2178 
c-Met Cell Signaling 8198 
Western blotting 
Materials and Equipment 
Producer 
Catalogue  
number 
Pierce™BCA Protein Assay Kit Thermo Scientific, USA 23227 
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4-12% Nu-PAGE Bis-Tris 
1.0mm x 12-well gel 
Novex for life sciences, 
Invitrogen 
NP0322 BOX 
See Blue®Plus 2 prestained standard Invitrogen LC5925 
Immobilon PVDF transfer membrane Millipore IPVH00010 
Mini-cell and XCellII™ Blot module Invitrogen, Novex 92008 
MES SDS electrophoresis Running 
buffer 
Invitrogen, USA NP0002-02 
Bovine Serum Albumine (BSA) Sigma Life Science A3294 
Super Signal® West Dura extended 
duration substrate 
Thermo Scientific, USA A 34076F 
Membrane visualization Chamber 
G:Box 
Syngene  
NaCl Sigma® Life Sciences S9888 
Tris pH 7.5 Merck 77-86-1 
Protease inhibitor Roche 04693159001 
Phosphotase inhibitor Roche 4906845001 
Seahorse® metabolism assay 
materials 
Producer 
Catalogue 
number 
XFe96 analyzer Seahorse®  
XFe24 analyzer Seahorse®  
96-well culture plates Seahorse®  101104-004 
24-well culture plates Seahorse® 101037-004 
calibration solution Seahorse® 102353-100 
96-well cartridges Seahorse® 102416-100 
24-well cartridges Seahorse® 102340-100 
DMEM medium Seahorse® 102353-100 
mito-stress kit Seahorse® 103015-100 
glycolysis stress-kit Seahorse® 103020-100 
Additional chemicals and equipment 
for metabolic assays 
Producer 
Catalogue 
number 
D – (+) - glucose Sigma® Life Sciences G8270 
L - glutamine Sigma® Life Sciences G3126 
sodium pyruvate Sigma® Life Sciences P2256 
DCA Sigma® Life Sciences 347795 
pico-green Life technologies P11496 
nano-drop 2000 Thermo Scientific  
Flow cytometry Producer 
Catalogue 
number 
Paraformyldehyde (PFA) Sigma® Life Sciences P6148 
Methanol Merck Milipore 106009 
12 x 75 mm Tube with 35µm Cell Strainer 
Cap 
BD Falcon 352235 
Hoechst 33258 pentahydrate Invitrogen H3569 
Pacific Orange life technologies P30014 
Cell tracker™ CM-DiL Invitrogen C7000 
BD LSRII Flow cytometer Becton Dickinson (BD), USA  
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Real time PCR Producer 
Catalogue 
number 
Trizol life technologies 10296010 
qScript™ DNA synthesis kit Quanta Biosciences 95047-100 
Thermo-cycler Gene-amp® PE Applied Biosystems 9700 
Nucleotide-Perfecta® super mix Quanta Biosciences 84008 
Real time PCR CFX-connect™ Bio-RAD   
Primers Sequence 
Universal 
probe 
MITF  
foreward: 
cattgttatgctggaaatgctaga 
reverse: 
tgctaaagtggtagaaaggtactgc 
#62 
MLANA 
left: gagaaaaactgtgaacctgtggt 
right: 
gactgttctgcagagagtttctcat 
#39 
LDHA 
left: gtccttggggaacatggag 
right: ttcagagagacaccagcaaca 
#47 
PGC1α  
left: tgagagggccaagcaaag 
right: ataaatcacacggcgctctt 
#13 
YARS  
forward: 
ggattaacaggcagcaaaatg 
reverse: ccttccgatcaaggagatca 
#35 
Table S.1 List of materials and reagents used in the study 
 
 
